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Key Recommendations 
1. Governments and all other stakeholders in better public health – including 
national and international level pharmacy – should work globally to ensure that 
due emphasis is placed on smoking cessation service provision via strong and 
comprehensive interpretations of Article 14 of the WHO’s Framework Convention 
for Tobacco Control.
2. Public and private health care providers should put in place adequate smoking 
cessation service funding mechanisms, commensurate with rationally defined 
local health improvement priorities.
3. All health professionals should recognise the still growing importance of tobacco 
use as a threat to health world-wide, and work in partnership with other groups 
– including pharmaceutical industry and voluntary sector agencies – to promote 
smoking cessation.
4. Pharmacy leaders and regulators ought to encourage appropriate investments 
in professional training, to allow pharmacists to play a full role in ending the 
global pandemic of tobacco related harm.
5. Pharmacists should seek to ensure an optimally accessible supply of NRT and 
other cessation support medicines, and give evidence based advice to customers 
seeking to quit smoking. Wherever possible they should pro-actively offer more 
sophisticated and effective cessation support.
6. People seeking to take a responsible approach to their own health and that of 
their families and communities should support public health programmes aimed 
at preventing smoking and, as tobacco use declines, the provision of universally 
available services to help tobacco users free themselves of their life threatening 
condition.
7. Governments, health care professionals and citizens living in the mature industrial 
economies with long-term experience of tobacco related harm should share their 
smoking cessation service experience with communities with less exposure to the 
health costs of smoking, while respecting the fact that development priorities 
change as societies become wealthier. 
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4 Ending the Global Tobacco Pandemic
Summary
The early stages of the present global tobacco pandemic were associated with the beginnings 
of greater wealth, and a rapid spread of the smoking habit in relatively advantaged individuals 
and communities. Its end stages are seeing tobacco use concentrated in relatively poor, less 
educated and more vulnerable populations.
Tobacco use remains the single greatest avoidable threat to public health worldwide. Total 
consumption of tobacco products is now falling in the mature industrial nations. But it is 
still increasing in many rapidly expanding economies. Without more effective action to 
curb global tobacco use, smoking will kill in the order of a billion people in the twenty 
first century.
Public health campaigns to prevent and reduce tobacco related harm are primarily based on 
controlling tobacco product prices and advertising, and limiting smoking in public places. 
But as smoking rates decline the requirement for individual cessation support services, 
aimed at helping individual tobacco users quit smoking, rises. Governments, professionals 
and the public should recognise the growing need for stop smoking support services as 
countries develop.
There is robust evidence that community pharmacies and pharmacists can be effective 
providers of smoking cessation support. Pharmacy can play a key role in ending the global 
tobacco pandemic. 
All pharmacists should supply smoking cessation and reduction products and give advice 
in response to customers’ questions. But more sophisticated pharmaceutical care further 
increases quit rates. Appropriate professional training and the service funding mechanisms 
necessary to ensure extended public access to smoking cessation support should be put in 
place by professional bodies and health care providers.
Important examples of enhanced pharmacy based smoking cessation services already exist 
in countries such as Denmark, the UK, the US, Canada and Singapore. In Northern Ireland 
there is a nationally funded system, based on a flat rate fee for supporting attempts. All 
nations will need to develop further their approaches to supporting citizens’ efforts to stop 
smoking, tailored to fit local traditions and development priorities.
Pharmacists are strengthening their contribution to improving public health. This will 
require enhanced partnerships with other private and public stakeholders in smoking related 
harm reduction, and increased professional self confidence. Government departments, 
public and private health care providers, pharmaceutical companies, non-governmental 
bodies and health care professionals should seek innovative ways of working together to 
extend public access to smoking cessation support.
The WHO’s Framework Convention for Tobacco Control (FCTC) is promoting global progress 
towards the elimination of mass tobacco use. Pharmacy as a national and international 
force for better health should support governments and other agencies in the ongoing 
implementation of the Convention, so that in future greater emphasis is placed on cessation 
service via a comprehensive interpretation of Article 14 of the FCTC.
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Tobacco use remains the single largest avoidable threat to 
public health in the ‘mature’ industrialised nations,1 even 
though its prevalence is now declining because of the 
implementation of prevention and control policies. Smoking 
is also gaining a similar significance in the faster expanding 
economies of the world, such as those of Asia. In many of 
the latter the use of cigarettes and other tobacco products is 
already high and, among many groups, still rising.
The reductions in population level life expectancy caused by 
tobacco use during the twentieth century were, in Europe 
and the United States, on a scale broadly comparable to the 
longevity gains generated by modern medicines. Globally, 
smoking is today responsible for in the order of 5 million 
premature deaths a year. In addition, it is a major cause of 
disability associated with cardiovascular and cerebrovascular 
disease and conditions such as chronic obstructive pulmonary 
disease (COPD). In China alone (where around a third of 
today’s smokers currently reside) in the order of 50 million 
people have already been impoverished because of the 
direct and indirect costs of tobacco related ill health.2 Such 
data have profound implications for pharmacists and other 
health and social care professionals seeking to maximise their 
contributions to health improvement. If unchecked current 
smoking trends will lead to the premature deaths of one 
billion people during the twenty first century, the majority 
of whom will be Asian.
In the United Kingdom – which was among the first countries 
to suffer large scale harm to public health due to cigarette use 
– mass awareness of the scale of smoking related morbidity 
and mortality was first promoted in the 1950s and early 1960s 
by pioneering public health doctors such as Professor Sir 
Richard Doll – Figure 1. In fact, overall smoking levels peaked 
at about the time the Royal College of Physicians published 
‘Smoking and Health’, a key report that also marked a tipping 
point in British medical opinion. From 1962 onwards most 
British doctors have accepted the fact that smoking is a major 
cause of cancer and heart disease. Medical leadership in this 
field, and the visible reality that doctors themselves began to 
quit in large numbers, in time opened the way to government 
action aimed at tobacco harm control (see Box 1) and the 
fuller involvement of other health professionals in smoking 
cessation and prevention. 
Against this history, this report highlights the potential of 
pharmacy and pharmacists to make an enhanced global 
contribution to smoking cessation and tobacco harm 
prevention. Key questions explored relate to the financial 
and professional incentivisation of pharmacists. This should 
enable them to take a pro-active role in promoting smoking 
cessation and encouraging the effective use of pharmaceutical 
aids such as nicotine replacement therapy (NRT), alongside 
other forms of behavioural change support. Present structural 
and cultural barriers to pharmacists’ involvement in this field 
are also considered. 
As tobacco control policies take effect smoking becomes 
seen as an unhealthy – pathological, rather than normal and 
socially accepted – habit. The provision of services aimed 
at enabling individuals to stop should then emerge as an 
increasingly important political and health service priority. 
There is evidence that accelerating the introduction of quit 
support provisions world-wide could (over and above the 
impact of other interventions to prevent smoking) save some 
10 million lives by 2050.3 Growing international awareness 
of the importance of this opportunity is reflected in current 
attempts to implement comprehensively Article 14 of the 
WHO’s Framework Convention on Tobacco Control (the 
FCTC). The latter addresses smoking cessation support, 
but is not (at least as yet) always seen as obliging WHO 
member states that have signed the FCTC to ensure that their 
populations have access to effective services.4
Introduction
* Hu et al (2007) have recently estimated in the US context that a 10 per cent increase in over-the-counter sales of NRT can be expected to lead 
to a 0.04 per cent decrease in tobacco sales. Given that in cash value terms the US tobacco market is over 100 times that of the NRT market, 
this on an equivalent scale basis suggests that a 10 per cent increase in NRT use corresponds with a 4 per cent cut in tobacco spending.
Figure 1  Cigarette smoking in the United Kingdom per 
capita per annum, 1905-2005
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There is also extensive evidence that pharmacists are able cost 
effectively to provide smoking cessation support to individuals 
and communities.5-22 The available research indicates that 
specialised training increases the likelihood of pharmacists 
discussing tobacco use with their patients/customers and 
that this leads to enhanced service user satisfaction.23-25 But 
the extent of pharmacists actual involvement in the delivery 
of stop smoking services is often very limited.26-28 Even in 
‘developed’ national settings it may frequently involve no 
more than the supply of brief ad-hoc advice on NRT and/or 
other medicines use. This does not optimise quit rates, or the 
contribution of pharmacy to health improvement. 
Facilitating good access to products such as NRT is beneficial 
at both an individual and a population level.* Even without 
additional support for tobacco users this will either reduce 
smoking amounts (through substitution) or, in a proportion of 
cases, facilitate quitting.30,46 However, well designed pharmacy 
smoking cessation services – incorporating appropriate 
forms of remuneration and professional practice support 
and management – are needed to provide the best outcomes 
for service users. Given this, a secondary question addressed 
during the research for this report was ‘to what extent can and 
should the relatively comprehensive systems for incentivising and 
supporting pharmacy/pharmacist provision of smoking cessation 
services in countries such as England, Scotland and Northern 
Ireland serve as models for similar developments elsewhere?’ 
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The first main section below provides further information on 
the course of the global smoking pandemic, and the ways in 
which communities across the world have so far responded 
to the public health threat it represents. The next reports 
the results of a survey of UK National Health Service (NHS) 
community pharmacy based smoking cessation service 
provision. The third presents findings of a second survey on 
the international development of pharmacy based smoking 
cessation services. The final section discusses a range of factors 
that may influence the world-wide capacity of pharmacy to 
fulfil its potential in this key area of health protection and 
improvement.
Financial payments alone are by no means the only factors 
relevant to the involvement of pharmacists in smoking 
cessation support. Pharmacists’ education and training, and 
the expectations and motivation of the public and other 
health service providers and their funders, need adequately 
to be appreciated. In time pharmacists may well – with the 
ongoing computerisation and mechanisation of the physical 
supply of medicines – no longer be needed to dispense in a 
narrow sense of that term. Rather, their twenty first century 
role is likely to focus more on promoting clinically and 
socially optimal patterns of medicines use, along with other 
forms of health behaviour change.
Hence the viability of the profession may in future rest 
much more than is presently the case on its ability to 
adapt and lead in areas like supporting smokers who wish 
to quit. Seen from this perspective, developing smoking 
cessation services represents a bridge to tomorrow’s practice 
that pharmacists can ill-afford to neglect. If pharmacy is 
successful in becoming a leading global source of smoking 
cessation support the profession will have helped to secure 
not only its own survival, but that of many millions of 
people who will otherwise – unless further action is taken 
– die prematurely.
National and professional stages 
of change
To open the way for pharmacists and other health 
professionals to provide tobacco cessation services that have a 
population level impact a series of interlinked social, political, 
professional and public health developments are likely to 
have first taken place. Figure 2 highlights several of these 
necessary phenomena. They are all closely associated with 
the processes that accompany socio-economic development. 
In its early stages industrialisation has often been linked 
with increased tobacco use. But as economies continue to 
mature populations tend to become more health aware, and 
increasingly concerned to prevent illness wherever possible. 
Hence tobacco use declines.
Box 1. Controlling Tobacco Related Harm
During the last two decades bodies such as the WHO and 
the World Bank have emphasised the overall economic 
as well as the specific health benefits of diverting 
resources away from the production and use of tobacco 
towards more productive goods and services. The main 
options available to policy makers to help communities 
prevent and reduce smoking and smoking related harm 
include:
j  Informing the public. In addition to providing 
appropriate education to children and other sections 
of the public, clear health warnings on tobacco 
products can help reduce their consumption. 
j  Raising prices. In higher income countries a ten per 
cent increase of cigarette prices should lead to a four 
to five per cent decrease in volume consumption. 
This makes taxation aimed at maximising public 
health (as distinct from state revenues) a central tool 
of tobacco harm control. But to be effective in any 
given national or regional context such measures 
need to be backed by effective controls over threats 
such as the illegal importation of tobacco products 
from lower price areas
j  Regulating effectively tobacco sale and 
advertising. This may involve the prevention of 
cigarette supply to minors, and controls over – and 
bans on – tobacco advertising. The use of misleading 
product descriptors such as ‘mild’ and ‘light’ may be 
prohibited, as can sponsorship programmes aimed 
at, say, associating smoking with sport and health 
or health research.
j  Implementing environmental controls. Bans 
on smoking in enclosed places protect the wider 
public as well as smokers themselves, and also serve 
to reduce indirect risks such as those of fire.
These and similar measures all represent relatively low cost 
ways of influencing the behaviour of entire populations. 
As such it is typically the case that governments often 
prioritise such action over and above the public provision 
of smoking cessation support. But as overall tobacco 
consumption rates fall, the needs of sections of the 
community less able (for social and/or biological reasons) 
to stop using nicotine containing products become more 
apparent. The impact of additional tax rises and other 
control measures will decline, unless complementary 
treatment based interventions are made. At the same time 
wider social values change, so that people using facilities 
such as pharmacies become more likely to expect and 
welcome inquiries about their use of tobacco.
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Figure 2  Factors influencing pharmacy-based 
cessation service development
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Tobacco use and demographic and 
epidemiological transition
Tobacco use in Europe dates back to the mid 16th century. But 
it only became a mass habit with substantive effects on public 
health in the twentieth century, initially during the later 
stages of North Western European demographic transition 
(Figure 3). In the context of countries such as Britain and the 
United States (the demographic and social development of 
which has largely coincided with that of Western Europe) the 
introduction of efficient cigarette manufacturing technologies 
and the impacts of the two twentieth century ‘World Wars’ 
were significant contingent factors in the early history of 
(male) mass tobacco use. Because of social factors, women’s 
smoking rate increases (and eventual declines) tend typically 
to be moderated in scale, and to lag behind those observed 
in men by a few decades.
Demographic transition normally starts as a result of early 
stage industrialisation and increases in agricultural efficiency. 
Populations become better fed, and in time gain increased 
access to other goods and services. This is initially protective, 
and is associated with falling infant mortality rates and rapid 
population growth. However, as wealth continues to increase 
and birth rates in time fall, populations age (that is, the 
proportion of older people rises) and gain greatly increased 
access to diets rich in animal fats and sugars. They also typically 
increase their consumption of other potentially harmful 
items, such as alcohol and tobacco products. Countries like 
Britain and France went through this development phase in 
the nineteenth and twentieth centuries: China and India are 
in the process of following them towards a state of very low 
mortality balanced by very low birth rates.
young as the major cause of death to a situation in which most 
people die in later life from conditions such as cancer and 
heart disease. One consequence of this pattern of events has 
been that in Europe and America better health and increased 
survival resulting from economic progress in the first half of 
the twentieth century paradoxically tended to conceal the 
true level of harm being caused by increased smoking, because 
the ill health it caused was mistakenly taken to be a normal 
consequence of ageing. That is why the publicly funded 
(as distinct from private, self purchase based) provision of 
interventions such as quit support services has only recently 
become seen as a public and political priority, decades after 
the ‘mature’ industrial societies first began devoting massively 
increased resources to the treatment of conditions like late stage 
cancers, heart failure and obstructive lung disease
The spread and then eventual decline of tobacco smoking 
can therefore be regarded as a reflection of fundamental 
development processes. At a population level tobacco 
use typically begins among relatively affluent males in 
communities that are emerging from poverty. In modern 
Europe smoking as a mass habit is now starting to end: it 
remains most prevalent amongst the last social groups to 
become relatively wealthy and empowered, who by definition 
tend to be poorer women and men. Problems such as obesity 
and smoking related harm do not differentially affect less 
advantaged people in very poor countries. It is as populations 
become more affluent that they have to face problems 
associated with increased access tobacco and other health 
hazards. This is especially challenging when combined with 
the ongoing relative social and cultural poverty experienced 
by less successful groups within wealthier communities.
Following on from this, Figure 4 reflects the lagged sequence 
of events that characterises the current phase of global tobacco 
pandemic. While countries such as the UK, the US, Australia, 
New Zealand and Canada are now seeing reductions in 
smoking and declining male (but typically still rising female) 
tobacco-related mortality, those of southern and eastern 
Europe and nations like China, India and Japan (which 
entered demographic transition surprisingly late) have not 
yet fully experienced the health impacts of increased smoking 
rates in men, or indeed women. 
It remains to be seen whether or not there will in today’s 
emergent economies eventually be a surge in smoking-related 
harm in women on a scale like that presently observable in 
North West Europe. It might be possible to avoid this hazard 
as new patterns of social development progress. In the case of 
China, for instance, reported rates of female smoking remain 
low. But this may be partly due to the stigma attached to 
women smoking.* In younger more educated women true 
smoking rates may already be in the order of 30 per cent,31 
compared with around 70 per cent in all adult men.
International Policy Development
Against such global trends in smoking and social development, 
the WHO Regional Committee for Europe approved its 
European Action Plan on Tobacco in 1987. This was 
followed by the 1988 ‘Charter Against Tobacco’ which 
identified strategies for achieving a tobacco-free Europe. It 
described a phased approach to tobacco control. Following 
* Chinese research also shows male smoking rates to be relatively high in rural as opposed to urban communities. Although the available 
data indicates – as elsewhere in the world – a positive elasticity of demand for tobacco products of around 0.5 (that is, if prices rises by 10 
per cent consumption will fall by about 5 per cent), higher levels of education (and by implication income) are already in men becoming 
associated with lower levels of tobacco consumption. This may imply that with regard to tobacco use China’s social development, at least 
in city and allied settings, is capable of proceeding very much more rapidly than might on occasions be assumed.
Figure 3  Demographic transition in North Western 
Europe and the United States
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Decreased physical activity and increased food and tobacco 
consumption for a period tend to offset the health gains of 
the transition process in older people, until the latter become 
more aware of lifestyle threats to their long term survival. There 
is a clear public health opportunity for emergent economies 
and transforming societies such as that of, say, modern China 
to learn from the past harm experienced in Europe and North 
America, and seek rapidly to cut short the smoking pandemics 
that threaten their citizens’ future wellbeing.
Demographic transition leads on to epidemiological transition. 
There is a shift from infectious illnesses amongst the relatively 
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proposals led by the WHO’s EuroPharm Forum (European 
Forum of Pharmaceutical Associations) the second stage of 
this programme included a project aimed at encouraging 
‘pharmacies to become smoking cessation centres’. 
A third phase was initiated in 1997, at which time the value 
of the work undertaken by EuroPharm group was formally 
recognised. Shortly after this, work on the development of 
the WHO’s Framework for Tobacco Control (FCTC) began 
in earnest. The FCTC was adopted in 2003, at the 56th 
World Health Congress. Despite some possible weaknesses, 
it provides a legally based international template for the 
introduction of comprehensive policies aimed at promoting 
a world-wide decline in tobacco use.
Such policy developments are important, and should be 
taken further forward. From a smoking cessation perspective 
a robust and comprehensive implementation of Article 14 of 
national level through the use of a comprehensive evaluative 
instrument.33 Figure 5 presents data from this study. It 
contrasts selected country scores (which were the sum of 
sub-scores for action on tobacco prices, public place smoking 
bans, spending on public information campaigns, advertising 
bans, health warnings, and treatment provision) with the 
treatment provision scores alone. The latter are based on the 
availability of quitlines, funding for cessation networks and 
funding for pharmaceutical smoking cessation aids. 
Although the design and application of this scale might be 
further improved, these results provide a valuable overview 
of the extent of the progress already achieved in European 
countries. In the context of international pharmacy policy and 
pharmaceutical care improvement one challenge to address 
is whether or not a global tobacco use cessation support 
development assessment instrument could be produced. The 
aim of this would be to identify and prioritise the actions 
needed to improve ‘stop smoking’ services and allied public 
health activities in given national contexts. Figure 6 outlines 
what such an instrument might seek to measure.
The use of ‘stages of change’ (SoC – TransTheoretical Model 
based) in the care and support of individual smokers has 
– despite its popularity with many health practitioners – been 
criticised, partly for encouraging deterministic thinking.34, 35 
Assumptions that people have to go through a fixed sequence 
of cognitive adaptation in order to stop smoking can lead to 
professional time being wasted on unproductive attempts to 
‘stage’ potential quitters. A simplistic approach to applying 
systems level SoC models could also have unwanted 
consequences. 
Nevertheless, the national level introduction of smoking 
cessation services can in the context of this report usefully be 
perceived as an incremental social process, divided into four 
main stages. As Figure 6 indicates, these encompass multiple 
processes of preparation, development and implementation 
of public health policies for tobacco control. Complementary 
smoking cessation support becomes more important as the 
smoking habit becomes ‘pathologised’ – that is, as it becomes 
regarded more as a sickness to be treated than as a normal 
behaviour. This sequence of development is part of wider 
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Figure 4  Stages of the present tobacco pandemic32
the FCTC (the only part of the Convention which mentions 
cessation service provision) could in future facilitate the 
development of new quit services. This may cost effectively 
complement the impact of more traditional public health 
interventions such as increasing public knowledge of the 
harm caused by tobacco products, increasing their price, 
restricting their advertising and preventing their use in 
circumstances where the inhalation of tobacco smoke could 
cause harm to non-smokers. 
It would be naïve, and perhaps counter-productive, to 
regard any form of fundamental social development as 
being primarily driven by high level international policy 
interventions. National and community level priority setting 
processes need to be respected, and it ought to be recognised 
that in some parts of the world (such as sub-Saharan Africa 
countries with high rates of HIV/AIDs and tuberculosis) 
supporting smoking cessation may not immediately seem to 
be a key objective. However, even in settings such as these 
stopping smoking can bring unexpected gains. For example, 
it can help to enhance overall treatment outcomes for 
conditions such as pulmonary tuberculosis. It would also be 
unwise to underestimate the extent to which country level 
policies may be driven by international comparisons of their 
performance in high profile areas of health and social care 
provision and measurable public health status.
Towards a staged model of tobacco control 
development
In the European context a recently published study by 
Joosens and Raw has attempted to quantify the introduction 
and implementation of tobacco control policies at the 
Ending the Global Tobacco Pandemic 9
long term shifts in the balance of health care’s focus between 
acute treatment, chronic condition care and health protection 
and promotion. 
Pharmacy can also be seen as progressing in a step-wise or staged 
manner, in parallel with regulatory action and reaction, albeit 
that an unduly mechanistic or simplistic interpretation of this 
process should once again be avoided. In Europe, for instance, 
Denmark is a country where pharmacist provided smoking 
cessation services is highly developed. A pilot study to generate 
evidence on the role of pharmacists in smoking cessation 
commenced there in 1986. By contrast, in Norway (another 
advanced Scandinavian country) an equivalent pilot study was 
not initiated until 2006. This limited example illustrates the 
larger point that local ‘contingent’ variables influence the timing 
and nature of specific national events, albeit that underlying 
trends are normally relatively consistent across world regions.
Stop Smoking Services in the 
United Kingdom
In the UK the development of publicly funded smoking 
cessation support services delivered via community pharmacy, 
including both free or low cost NRT supply for limited 
periods and ‘item of service’ fees to pharmacists for providing 
behavioural change support, reflects the fact that Britain is in 
an advanced stage of its historical experience of the tobacco 
related harm pandemic. It has also evolved because of specific 
factors relating to the structure and ethos of Britain’s NHS, 
and the functioning of the public health arm within it. 
As noted in the introduction, British mass awareness of 
smoking related harm was first promoted in the 1950s and 
early 1960s by individual leaders and professional bodies 
such as the Royal College of Physicians. But it was not until 
1998 that the government policy White Paper, Smoking Kills,36 
initiated the public funding of the organised tiered system 
of smoking cessation support outlined Figure 7. The precise 
details of the services available vary between and within the 
four UK nations. But broadly, in addition to self care support 
supplied by community pharmacists during the supply of NRT 
and other quit aid products, the services now in place range 
from the local provision of brief (level 1) advice by general 
medical practitioners (GPs) and pharmacists offered as part 
of their core NHS role through to the provision of specifically 
funded (level 2 and 3) individual and group support provided 
by specialists working in community and clinic settings.
The scale of these activities is illustrated by the fact that in 
England alone NHS providers operating at level 2 and above 
encouraged more than 500,000 quit attempts in 2004/05, of 
which some 250,000 were successful at four weeks. It is likely 
that these figures will have translated into 40,000 successful 
quit attempts at one year. Both published sources and research 
undertaken during the preparation of this report (see below) 
indicate that at least 20 per cent of such cessation service 
Figure 6  A preliminary step systems model – public, regulatory and pharmacy progress towards tobacco use cessation
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Figure 7  Levels of tobacco cessation service in the UK
PHARMACY   Public health role for pharmacy adopted in practice; national standards for cognitive/clinical services
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   Professional support for self care developing
GOvERNMENT  Comprehensive range of tobacco control interventions supported
   NRT freely availablew and licensed cessation product supply publically funded
PUBLIC   Universal awareness of tobacco-related harm; widespread acceptance of cessation opportunities
4
PHARMACY   Pilot studies for cognitive services in tobacco use cessation & other fields
   Growing awareness of clinical role & public health potential
GOvERNMENT  Partial approached to tobacco control introduced
   Medical prescribing of NRT supported, self-purchase encouraged
PUBLIC   Widespread public awareness of tobacco-related harm but still high rates of 
   smoking in socially disadvantaged groups
3
PHARMACY   Dispensing of medicines central fo pharmacy role
   Clinical/public health community pharmacy confined to pioneers
GOvERNMENT  Chronic and preventative care needs initially addressed
   NRT licensed but not publicly funded
PUBLIC   Limited awareness of benefits of cesation; socially advantaged groups begin to quit
2
PHARMACY  Professional supply of medicines in more advantaged communities; 
   unregulated distribution in less advantaged communities
GOvERNMENT  Focused on acute health concerns; tobacco use may be supported
PUBLIC   Little or no awareness of tobacco-related harm, smoking may be seen as beneficial
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provision – and in some instances substantially more – was 
and is delivered by community pharmacists.
The Royal Pharmaceutical Society of Great Britain (RPSGB) 
has recognised health promotion as a core pharmacy activity 
for many years. Since 1995, for instance, British community 
pharmacists have been required to display health education 
materials. Since 1999 they have been encouraged by 
their professional body to provide structured packages of 
behavioural support to aid smoking cessation, in addition 
to ad hoc help regarding the use of pharmacotherapies such 
as NRT and bupropion. 
Recent reforms in community pharmacists’ contractual 
arrangements with the NHS have confirmed that supporting 
‘self care’ level smoking cessation attempts via, for instance, 
offering brief advice to pharmacy users presenting with 
respiratory problems or spontaneously purchasing NRT is 
regarded as a ‘core’ or ‘essential’ service. All pharmacists 
receiving any dispensing or other fee from the NHS should 
automatically offer such pharmaceutical care, albeit that the 
quality of this general provision is not normally effectively 
monitored. However, smoking cessation services offered at 
levels 2 and 3 are classified as ‘locally enhanced’ interventions. 
The Primary Care Trusts (PCTs) in each area are responsible 
for purchasing (or, in NHS terminology, commissioning) 
more intensive forms of smoking cessation support from 
pharmacists and other providers, and that additional locally 
negotiated item of service fees are paid for its provision. 
Lessons from Local Service Development
The Healthcare Commission is an inspectorate charged with 
assuring the quality of NHS services in England and Wales. 
In 2007 it published an evaluation of Primary Care Trust 
(PCT) provided smoking cessation services.37 Nationwide, 
a third of these were rated as excellent and more than 
half as good overall. Those that scored most highly were 
said to collaborate with and work effectively with partner 
organisations and local authorities, to have promoted patient 
and public involvement, and to have invested in workforce 
development. This analysis suggested that the relative 
success of tobacco control efforts in the UK is related to the 
optimisation of public-private partnerships, a finding which 
might have international relevance.
For the purposes of the work presented here, the Commission’s 
report (which was entitled ‘No Ifs, No Buts’)37 provided a 
useful starting point for a further investigation of the roles 
and experiences of pharmacists in giving smoking cessation 
support in the NHS setting – see Box 2. A tabulated description 
of the observations made as a result of a brief survey of 
English PCT and other selected smoking service co-ordinators’ 
and participants’ views is contained in Appendix 1 of this 
report. Some of the most important examples of high quality 
pharmaceutical care provision were offered by respondents 
in Northern Ireland and Scotland.
For example, an in large part community pharmacy based 
smoking cessation service in Northern Ireland has been in 
place since December 2006. Building on previous innovations 
in service provision pioneered by pharmacists such as 
Dr Terry Maguire, this operates with a uniform structure 
across the whole of the country, which has a population 
of approximately 1.7 million. In addition to the cessation 
services uniform national structure it embodies a number of 
other important characteristics, such as:
1. Offering pharmacists a flat rate 4-week course payment 
of £28 (circa $55 US, E40) per patient/user regardless of 
whether or not a successful quit is recorded, coupled with 
an additional £7 for a 52 week cessation (cotinine-based) 
monitoring check.
2. The introduction of what is in effect a pharmacy 
prescribing budget, running parallel with, but separate 
from, the GP prescribing budget.38,39 This is an important 
innovation, which might in time serve to take forward 
other forms of pharmacy prescribing. 
Internationally significant points to draw from the Northern 
Irish model relate to the advantages of simple and robust item 
of service payment mechanisms, and the potential benefits 
of introducing pharmacy specific budgets for the provision 
of ‘pharmaceutical public health’ services. The latter may 
be defined as forms of extended pharmaceutical care and 
behavioural change support that receive public (either in 
addition to or in place of private) funding because they are 
aimed at achieving population level health gains in contexts 
where significant numbers of the intended beneficiaries 
Box 2. No Ifs, No Buts
The Healthcare Commission analysed the performance of 
PCT smoking cessation services according to their levels 
of social and economic deprivation. Excellent services 
were identified at all levels. For instance, more affluent 
areas with effective provisions included Richmond (where 
community pharmacists are responsible for 50 per cent 
of positive results) and Worthing (where pharmacy 
contributions appear not to be so extensive). At the 
other end of the spectrum high quality services were 
also found in poorer localities such as Newcastle, North 
Tees and Islington. Once again the level of pharmacy 
involvement varied between these sites, but was judged 
by School of Pharmacy researchers to be important in 
some. However, respondents in the best performing PCTs 
universally acknowledged the potential of pharmacy to 
play an extended role, despite noting budgetary restraints 
as a key limitation in many instances. Appendix 1 offers 
reports based on a total of 16 localities, derived from 
telephone and personal interviews and documentation 
provided by respondents.
Good practice in smoking cessation service provision 
was, as noted in the main text, found to be positively 
associated with active stakeholder consultation on the 
part of the provider PCTs. Illustrations of the actions 
taken as a result of consultation encompass:
j  increasing the number of community venues 
offering stop smoking services;
j  increasing the provision of out of normal working 
hours access options;
j  piloting drop in sessions in hospital wards, such as 
cardiac care and prenatal care facilities;
j  arranging group reunion sessions to share success 
experiences;
j  improving written information supplied by the 
NHS;
j  addressing the weight gain problems experienced 
by some quitters;
j  providing additional training for some staff; 
j  adjusting the range of NRT products supplied to 
meet user preferences; and
j  enhancing the monitoring NRT prescribing and 
spending.
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cannot afford, or may be unwilling to self purchase, relevant 
goods and services.
Other important opportunities for reducing tobacco related 
harm identified by agencies such as the National Institute 
for Health and Clinical Excellence (which has taken on an 
extended public health role) include reducing smoking rates 
during pregnancy and enhancing work place based access to 
cessation support. Respondents to The School of Pharmacy’s 
UK survey reported NHS local service initiatives in these and 
other fields.
An illustration of a successful Scottish approach to supporting 
quit attempts is that of Glasgow’s Starting Fresh smoking 
cessation project. Like the recent Northern Ireland initiative, 
this serves a relatively large area/region. Greater Glasgow has 
population of over 2 million. A third of adults there smoke. 
In some less advantaged communities in the city more than 
50 per cent of adults smoke, and one in every five persons 
dies of the habit. (For comparison, only about 20 per cent of 
US and Australian adults now smoke. This is well below the 
UK and European average rates.)
The project has created a network of over 150 accredited 
community pharmacies across Greater Glasgow. It aims to 
offer an easily accessible, cost effective, system for providing 
NRT and other forms of smoking cessation support. The 
Glasgow scheme offers pharmacy based counselling services 
and funds appropriate forms of medicines supply over 
12- week periods. The Starting Fresh Glasgow Stop Smoking 
Project involves both qualified pharmacists and counter 
assistants, and has systems for ensuring interventional quality 
and relevant process and outcome data recording. Its scale 
and approach once again has the potential to serve as an 
international example, albeit that countries and/or regions 
lacking nationally financed health care systems must foster 
alternative (social insurance system based or local taxation 
supported) ways of funding and co-ordinating ‘free at the 
point of use’ pharmacy based cessation support.
Turning to The School of Pharmacy’s survey findings in 
England, pharmacy policy and service development points 
worth particular attention include the following:
j  Most UK pharmacists/pharmacies appear broadly 
satisfied with relatively modest payments for stop 
smoking service provision, although their motivation 
is complex and influenced by a wide range of 
additional factors
The financial incentives offered to community pharmacists 
in England vary from around £20 ($39, E29) per successful 
quitter to £90 ($177, E32). The median community pharmacy 
payment is circa £45 ($88, E66) per quitter. Remuneration 
is markedly less for an unsuccessful quit attempt in some 
schemes. But there appears to be no significant link between 
the amounts paid and the level of pharmacy commitment 
and performance observed. One respondent commented 
‘the money is a hygiene factor, not a key driver. It has to be there, 
but factors such as professional and personal commitment are in 
my view more important’. This conclusion is endorsed here, 
albeit that if more significant sums were offered this could 
well have an appreciable (and perhaps on occasions perverse) 
behavioural impact. Some small pharmacies operating on the 
margins of economic viability might change their behaviour 
more markedly than others in response to a large increase in 
payment. A London chain store manager with responsibility 
for around 100 outlets said ‘there is no need for more money 
– we’ll take it, of course, but [providing level 2 smoking cessation 
services in pharmacies] is already economically viable’.
j  Requiring pharmacists/pharmacies to invest in 
quit support service establishment can increase the 
likelihood of their sustaining their effort to provide 
appropriate pharmaceutical care in the medium to 
long term
The Charnwood and Northwest Leicestershire PCT scheme 
differs from many others in that it requires community 
pharmacies to initially invest £300-£400 (up to $790, E590) 
into the set-up of the service before being invited to sign a 
contract. This covers the costs of training and the purchase 
of carbon monoxide (CO) monitors. PCT funds freed by this 
have been used to double the payment for a successful quit 
attempt from £25 to £50. It appears that due to the initial 
investment by community pharmacies in the scheme, there 
is greater commitment and hence more consistent provision 
of services. One individual involved in developing this 
arrangement said that it was in the past disheartening to 
see the level of commitment wane when new services were 
introduced, as compared to the enthusiasm expressed at the 
time of planning. It was commented that ‘if the NHS pays 
for everything upfront, they will all say yes’ and noted that two 
types of pharmacists exist – those who see the economic 
opportunity associated with supporting smoking cessation 
and provide the service effectively and those who are neither 
financially nor professionally motivated, but attend the initial 
training because ‘it looks good’.
j  A majority of English pharmacists appear to favour flat 
rate payments rather than variable schedules which 
give a lower payment for failed quit attempts and a 
higher one for successful attempts, even though the 
latter may in aggregate terms offer greater profit
A manager based in Haringey noted that introducing a 
supplementary payment to community pharmacists of £150 
($295, E220) per group of 10 service users who quit for four or 
more weeks (in addition to the overall fee of £45 paid per case 
handled, and returns associated with supply of NRT) had failed 
to provide additional motivation. In 2006/07 this PCT offered 
community pharmacists an additional £750 ($1,470, E1,100) 
per set of 50 four-week quitters achieved. But concerns remain 
about the impact of this enhanced incentive. The respondent 
also explained that an alternative Haringey scheme involving 
a payment of £70 per successful four-week quitter, but with 
no payment at all for failed quitters, successfully motivated 
practice nurses. But it was not favoured by community 
pharmacists. The latter apparently prefer the security of a lower 
level incentive payable independently of the case outcome. 
This would be consistent with the hypothesis that they tend 
to be financially (and perhaps otherwise) risk averse.
j  Large as opposed to smaller pharmacy chains and in-
dependently owned pharmacies may respond differ-
ently to given incentives, because of their contrasting 
business models and operational requirements and 
capabilities. (NB: in the UK pharmacies can be owned 
by corporate bodies as well as individuals, with a single 
pharmacy superintendent taking ultimate responsibil-
ity for the professional governance of a large number of 
community pharmacies.)
One experienced PCT cessation service manager commented 
that the apparent lack of success of individual incentivisation 
programmes may be in part due to the reality that many 
pharmacy chains do not normally enable individual pharmacist 
employees to receive personal bonuses from the NHS. This 
respondent reported that this is sometimes – rightly or wrongly 
– regarded as ‘company theft’. Others were critical of super-
market based pharmacy (some professionals located in such 
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settings were said to be motivated more by in house product 
sales targets than cessation rates per se) and concerned about 
the performance large national chain pharmacies as compared 
with smaller ‘local chain’ and larger fully independent 
pharmacies. Staff located in the latter may be more likely than 
others to enjoy more robust local links, and values seen (at 
least by lower level staff) as being more consistent with those 
of the NHS and PCT based service commissioners. However, 
some pharmacists in large chain pharmacies were also said 
by interviewees to have exceptionally high professional 
standards. Continuous staff movement between stores in 
different localities is commonly seen as a problem for large 
chain pharmacies because of its impact on local professional 
and allied relationship building.
Against this, multiple outlet pharmacy managers questioned 
appeared to be adequately motivated by the availability of 
PCT payments for smoking cessation service provision. But 
local variations in paper work and service requirements from 
their perspective act as a barrier to deploying their staff in 
an optimal manner. The implication of this is that bigger 
pharmacy groups would favour the introduction of larger 
scale, Northern Irish or Glasgow type, models in England 
and other countries where chain pharmacies are permitted. 
Respondents working in such settings also argued that greater 
uniformity in service provision would empower service 
users, by enabling them to develop clearer knowledge of 
consistently available service entitlements.
Although (as already noted) employee pharmacists do 
not normally directly receive NHS incentive payments 
for smoking cessation service provision, respondents also 
stressed that they may in larger organisations enjoy group 
and/or individual bonus payments linked to collective and/or 
individual performance. Further, one PCT manager noted 
that the most enthusiastic pharmacist in her locality is an 
employee pharmacist who receives no direct reward for his 
activities. He is a member of an ethnic community with high 
smoking rates that he is personally committed to reducing.
j  Effective incentives need not be directly financial
A pharmacist involved in tobacco cessation services at the 
PCT level, and who is currently part of a programme (in 
Islington) to mentor other local pharmacists in relation to 
their involvement in cessation, commented that providing 
pharmacies with equipment that could be used for tobacco 
cessation and other cognitive services can on occasions 
be a better motivator than offering direct cash incentives. 
This observation might be taken to conflict with one 
made previously on requiring pharmacies to invest in the 
establishment of cessation services. But in complex and 
variable fields incentivisation strategies should be tailored 
to specific circumstances. For example, in less well funded 
community pharmacies the only available computer may, 
with its printer, be exclusively dedicated to supporting the 
dispensing function. In such circumstances it could well be cost 
effective to provide pharmacies with additional equipment 
to document cessation service delivery, and provide tailored 
educational materials for potential quitters.
j  Some pharmacists lack the self confidence needed 
pro-actively to ask people about their tobacco 
use, and face other perceived barriers to involving 
themselves in smoking cessation support
Despite some apparent exceptions (as, for instance, in the 
case of Newcastle) it is a commonly observed pattern that 
even in areas with a strong focus on developing pharmacy 
based smoking cessation services and robust systems for 
providing relevant training and professional support, only 
a few community pharmacists – representing typically only 
10 per cent or less of the total number practicing locally 
– can be said to be fully engaged in smoking cessation 
service provision. This ‘motivated minority’ often accounts 
for the great majority of the quitters achieved via pharmacy 
interventions. (A large urban PCT with a population of 
500,000 might have an annual target of 3,000 four-week 
quitters, approaching a third of whom might be gained via 
pharmacy support.)
The suggested reasons for disappointing levels of active 
practitioner involvement in cessation support offered 
by School of Pharmacy survey respondents included the 
possibility that some pharmacists reject opportunities in this 
area because they do not see health behaviour change as the 
central role of pharmacy; the fact that notwithstanding the 
availability of cessation service payments the owners of many 
smaller pharmacies still believe that they and their staff lack 
the time for anything else but dispensing and direct sales 
activities; and a reluctance on the part of some pharmacists pro-
actively to question pharmacy users about smoking because of 
emotional and allied barriers. They may, for instance, fear that 
they will alienate their customers by behaving ‘intrusively’. In 
addition, pharmacists have also reported concerns relating to 
a low perceived probability of success associated with smoking 
cessation activities (see Box 3), poor communication with GPs, 
low public expectations of pharmacy and a lack of relevant 
prescribing rights and/or budgets in some areas.
Recommendations for the UK
Many other issues were raised during the course of this 
investigation of UK smoking cessation provisions. They 
ranged from the risk of corrupt claims being made by 
pharmacists for work that has not actually been undertaken 
(this type of hazard is universally present across all fields 
of human activity – despite concerns reported by one PCT 
involved in The School’s survey the possibility of incorrect 
payment claims being made cannot be said to especially 
affect community pharmacy) to the fact that as communities 
move towards giving up smoking it becomes harder for 
practitioners to find and help new quitters. This may be 
because residual smokers are more heavily addicted, or lack 
the social and allied forms of support which help others to 
give up the habit.
Aspects of these and other relevant matters are explored 
further later in this report. But the conclusions offered here 
relate primarily to the importance of examples of good 
practice such as the Northern Irish and Glasgow schemes 
described earlier. Their desirable characteristics, which may 
be regarded as recommendations for the UK as a whole to 
take up, include:
j  sufficient scale and uniformity to allow pharmacy groups 
of all sizes to use their staff members in an optimally 
effective manner;
j  the employment (in the case of Northern Ireland) of a 
simple flat level economic incentive, that pays the same 
for all individuals (quitters and non-quitters) completing 
a 4-week course, regardless of the outcome;
j  the effective establishment of an independent pharmacy 
prescribing budget for products such as NRT, to 
enable their appropriate free supply for the purposes 
of individual care oriented towards public health 
improvement; and
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j  a capacity for monitoring and verifying longer term 
quit rates, rather than simply using the four week self 
reported quit rate indicator employed in many English 
schemes.
Other recommendations that may add value to current British 
programmes include the suggestions that:
j  all pharmacy provided Medicine Use Reviews (MURs) 
and other pharmacotherapeutic evaluations should as a 
matter of routine include smoking behaviour assessments 
and follow up intervention planning; and
j  the smoking cessation service education and training 
available to community pharmacists and their staff is 
interesting, intellectually well-grounded, and delivered at 
a level and in a way likely to promote increased participant 
self-efficacy in the context of approaching potential 
quitters and asking about their smoking habits.
Looking beyond the United Kingdom, there is good reason 
to believe that – notwithstanding the differing funding 
systems underpinning other national health care systems, 
and the fact that national health improvement priorities vary 
between more and less affluent countries – an understanding 
of the NHS’ experience to date with pharmacy based smoking 
cessation support provision could help guide service formation 
elsewhere. It is to the world-wide development of pharmacy’s 
role in controlling, and ultimately ending, the global tobacco 
related harm pandemic that this study now turns.
Pharmacy’s international 
contributions to stopping 
smoking 
A second central component of The School of Pharmacy work 
reported here involved an international survey of smoking 
cessation service development, conducted in collaboration 
with the International Pharmaceutical Federation (FIP). The 
findings of this exercise, which involved respondents in 
thirteen countries outside the UK, are described in tabular 
format in Appendix 2. They can usefully be considered within 
the general framework of the analysis set out in the first main 
section of this paper. This is, from a pharmaceutical care 
development perspective, further elaborated in Figure 8.
Box 3. Cessation Support Success Rates
The effectiveness of interventions aimed at stopping 
smoking varies in different cultural contexts, and 
with factors such as the extent of the addiction to 
nicotine experienced by individuals and groups. The 
way in which quitting is defined and measured is also 
significant. However, the available literature indicates 
that success rates will typically vary from only 1-2 per 
cent at six months or over in populations given no 
professional or pharmacological support, through to 
approaching 20 per cent amongst groups given intensive 
sustained psychological support backed with appropriate 
medicines. 
There is robust evidence from European and US sources 
that brief advice from a physician can increase the basic 
quit rate to around 4 per cent,40 and that the use of NRT 
approximately doubles the probability of a quit attempt 
succeeding in any setting, regardless of other variables. 
Hence an average individual seeking to quit after being 
given brief medical advice and NRT should have a 7-8 
per cent chance of stopping smoking (see also text). More 
intensive behavioural support, including at the higher 
end group cessation therapy, can – as indicated above 
– produce significantly better outcomes. 
The evidence base on the extent to which brief pharmacist 
advice will enhance quit rates is not as robust as that for 
physicians. The relative efficacy of pharmacists might 
perhaps be highest in social settings where they are 
regarded as having a status equal to that of doctors, and 
in situations where people expect pharmacists to have 
a general concern for their health rather than being 
exclusively concerned with dispensing. But taking into 
account experience in more intensive cessation service 
delivery settings, there is good overall reason to believe 
that both pharmacists and nurses can be as technically 
effective in delivering smoking cessation support as 
members of the medical profession. In practice pharmacy 
based services may also enjoy additional advantages, such 
as ease of access.
Figure 8  Stages of cessation support service 
development – a guide for stakeholders in global 
pharmaceutical care improvement
Globally, effective tobacco control efforts involve three main 
elements.41 They comprise:
j  influencing the behaviour of current and potential 
tobacco users, by encouraging or obliging them to avoid, 
reduce and quit smoking; 
j  limiting and preventing tobacco industry attempts to 
promote smoking; and 
j  reducing the harm from use of tobacco/nicotine 
products, where possible and desirable by facilitating 
the use of safer alternatives.
The potential for pharmacy to effect lasting change in 
this arena is a function of the relationship between the 
profession as social and functional entity and the wider 
social, economic and health infrastructures of the countries 
in which pharmacists practice. It is also affected by the 
quality of individual professional contributions, and of the 
leadership of the profession at all levels. Even at similar 
stages of economic development, contingent variables such 
as these can have an important influence. For instance, in 
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some national environments (such as that of Malaysia) there 
have been notable attempts to improve pharmacy training in 
the context of smoking cessation service delivery. Elsewhere 
this has not been the case: pharmacists have on occasions 
somewhat passively adopted a role in this field in response 
to pharmaceutical industry initiatives, changing consumer 
demands and, on occasions, political leadership. 
General self care support forms the mainstay of global 
pharmacy tobacco cessation activities. Despite significant 
work over the last 30 years to highlight extended role 
opportunities, community pharmacy practice world wide 
remains largely tied to product dispensing rather than 
cognitive service provision and/or preventative health care. 
But the instance of tobacco use cessation illustrates how 
an initially supply based role can evolve to include more 
sophisticated interventions, with the potential to make 
significant contributions to better health outcomes at both 
the individual/clinical and population/public health levels.
In countries at stage 1 of the progression illustrated in Figure 8, 
merely optimising the delivery of brief advice and counselling 
associated with the sale/dispensing of NRT products and other 
cessation medicines can represent a significant improvement 
over the status quo. This requires actions within the scope of 
even the most traditional laws and assumptions governing 
pharmacy practice. In very poor countries, such as many of 
those in sub-Saharan Africa, the opportunities for pharmacists 
(who are few in number compared with the total population) 
to practice in this way may well be restricted to private service 
settings used by urban elites. But as it is members of the latter 
who are most likely to smoke tobacco in the initial stages of 
the pandemic, this is not necessarily inappropriate. If the 
groups offering role models for the wider communities of 
less economically developed nations can be persuaded to quit 
early, then others may be exposed to less risk of starting to 
smoke as they become wealthier.
Pharmacists working in stage 2 settings are more often 
in a position to address the needs of the general public. 
They should be encouraged to ask patients/pharmacy users 
proactively about their tobacco use, and to advise them that 
support of various types is available to help stop smoking. 
The available research indicates that referring pharmacy users 
to a programme such as a quit line typically adds less than 3 
minutes to a patient encounter. Further, such interventions 
can be delivered by technical staff during virtually any visit, 
including picking up prescriptions for other health needs. 
India is an example of a nation that might reasonably be 
considered to be in this developmental phase. It would 
be unwise (as with China) to generalise too much about a 
country with a total population twice the size of that of the 
European Union that has a large, well educated, professional 
middle class balanced by some 300 million people living in 
absolute poverty. The traditional patterns of tobacco use 
seen in India are in a number of respects unique, as also 
is the structure of the pharmaceutical profession (and the 
wider pharmaceutical sector) there.42,43 Nevertheless, the 
potential for Indian pharmacy and pharmacists to make a 
definitive contribution to public health protection though 
tobacco use control and quit related interventions should 
be recognised.
In countries at stage 3 (most EU member nations, the United 
States, Canada, Australia and New Zealand) studies of enhanced 
pharmacy based provision combining brief interventions and 
more intensive individual support programmes typically 
show good outcomes for those accessing such services, but 
disappointingly limited uptake rates. The implication of this 
observation is that more effective marketing of services to 
patients and referring medical practitioners would be in the 
public’s interest. 
Overall, the picture derived from The School of Pharmacy’s 
international survey, particularly as it applies to Europe, 
is consistent with that presented by Joosens and Raw in 
their work on applying their experimental Tobacco Control 
Scale33 (see Figure 5). Western European countries tend, 
not unexpectedly, to be more advanced than those in the 
Eastern areas of the continent. But within this pattern each 
nation state has its own local history and structures, within 
which the specific opportunities available for pharmacy 
based smoking cessation service development need to be 
understood.
The role of professional organisations and 
pilot studies
Pharmacy’s professional bodies have vital role to play 
in forming and applying strategies for achieving greater 
recognition for the profession in the sphere of tobacco 
control (and wider public health) leadership and cessation 
service provision. They can also, as countries move through 
to the later stages of the smoking pandemic, help support 
the introduction of adequately funded services aimed at 
reducing social class related inequalities in tobacco use, and 
the ill-health it engenders. This could in the immediate future 
demand high level pharmacy inputs into strengthening 
the implementation of the WHO’s Framework Convention 
on Tobacco Control, particularly in the context of article 
14. Robust interpretations of the latter should include due 
emphasis on the importance of supporting pharmacy based 
and other smoking cessation services.
In countries where the pharmacists’ public health role is 
not well established, professional bodies may initially need 
to focus on developing awareness amongst pharmacists 
themselves of their interests and capabilities in this field. For 
example, many nations celebrate Pharmacy Week, during 
which professional organisations promote the role of their 
members through (public) health and allied campaigns. The 
Indian Pharmaceutical Association (IPA) has organised action 
programmes for both World No Tobacco Day and National 
Pharmacy Week. Smoking cessation promotion kits were sent 
to individual pharmacists and pharmacies, state and local 
professional branches, and pharmacy education institutions. 
A similar campaign recently undertaken in Singapore was 
also aimed at encouraging the public to access community 
pharmacies for relevant advice.
Once awareness is generated amongst pharmacists and public 
expectations start to rise, professional bodies can seek to build 
on this bridgehead via further political, professional and 
public communications. They may also promote capacity 
building. In Malaysia, for example, there has been a focus 
on further skilling and certifying pharmacists for the delivery 
of smoking cessation services, despite there being as yet no 
formal public-private tobacco cessation scheme in place. To 
date, one third of community pharmacists in the country 
have been so certified. 
Such investments ought to open the way to ongoing processes 
of negotiation and partnership formation with other groups 
interested in achieving better individual and national health. 
These can involve evidence gathering and the organisation 
of pilot projects aimed at helping ensure that pharmacists 
are appropriately positioned to make viable, cost effective, 
contributions to tobacco use cessation in given settings. But 
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the value of some recent initiatives undertaken in countries 
such as Australia, Norway and Portugal appears to have been 
limited. This has in large been part due to the fact that uptake 
of services has been low. Insufficient attention is often paid 
to the task on enabling community pharmacists and their 
colleagues to actively find potential quitters.
Conducting and publishing pilot studies can contribute to the 
development of effective funding systems. In many countries, 
public (and/or universally accessible social insurance based) 
funding of tobacco cessation services and other cognitive 
services in pharmacies is not as yet available. Yet even in a 
prosperous highly developed nation like Norway more than 
half of the customers enrolled in a 2006 stop smoking pilot 
stated that they would not be willing to pay directly for 
pharmacy based tobacco cessation services. This emphasises 
the importance of the part that professional bodies can play 
in bringing the need to create effective financial support 
systems to the attention of governments and other health 
sector stakeholders.
Similarly significant examples of the international challenge 
to be overcome in relation to publicly funding adequate 
cessation services can be drawn from other affluent 
Scandinavian nations. In Finland, for instance, it is also the 
case that no cognitive pharmacy services are as yet funded via 
the Government. Pharmacies charge fees of up to 80 Euros 
(£55, $107) to the customer for cessation counselling, in 
addition to the cost of NRT. The evidence available indicates 
that this is an important barrier to service access. 
In Sweden, the government presently (via the currently 
nationalised chain, the Apoteket) holds a unique monopoly 
over the ownership of community pharmacies. While 
there has been investment in training primary healthcare 
providers of all types in the use of motivational interviewing 
techniques and encouraging them to support quit smoking 
attempts, the Swedish system has lacked specific mechanisms 
for the economic incentivisation of such forms of service 
provision. Customers who wish to have individual face-to-face 
counselling by pharmacists must pay a user fee of 60 Euro, in 
addition to the cost of NRT or other purchases. The Apoteket 
has recognised this as a barrier for many to accessing what 
is in health outcome terms one of the most cost effective of 
all forms of health care (Box 4). The organisation has stated 
that without specific government funding the expansion of 
smoking cessation service provision will be very difficult.
Translating research and experimentation 
into mass provision
The above survey findings do not necessarily mean that 
private market oriented and allied independent insurance 
based solutions to the problem of stopping smoking at a 
population level cannot be developed. There are, for example, 
promising pharmacy and related schemes in place in parts 
of the US, and present overall trends throughout the mature 
industrialised economies suggest that in time educated people 
and communities will naturally elect to quit tobacco use. 
But if policy makers wish to facilitate rapid change, and protect 
those least able (by virtue of their situations and/or personal 
attributes) to stop smoking before they suffer major harm, 
then the case for direct (or mandatory indirect) public funding 
is strong. It is also a fact that, although overall smoking 
rates in the US are low, some pharmacies and pharmacists 
working in unsupported market competition are discouraged 
from providing non-funded smoking cessation help. They 
may fear that their customers will accept uncharged advice 
and counselling, yet subsequently buy products like NRT 
medicines from lower cost sources that do not invest in 
cessation support.
Denmark is a country that, like the UK, has a central 
taxation based health care funding tradition. Although some 
commentators argue that aspects of its national approach 
to tobacco harm control could be strengthened, Danish 
pharmacy-led tobacco cessation services have been in place 
for some twenty years. For the period 2005-2008 Danish 
pharmacies have been allocated over 400,000 Euros per year to 
further enhance cessation services for the country’s population, 
which numbers just over 5 million people. The majority of 
the latter are covered via a system that offers pharmacies 170 
Euros ($230, £115) for each customer completing a six month 
programme, followed up at one year. 
Pharmacists are currently the most active providers of tobacco 
cessation services in Denmark. As with the UK examples 
provided previously, it would be unhelpful to suggest that 
the Danish system represents a model which all other 
countries could or should seek to emulate in exactly the 
same manner. But as across the world health care systems and 
tobacco control programmes continue to develop, the Danish 
arrangements provide a useful indication of what pharmacy 
might reasonably aspire to achieve.
Realising the pharmacy 
opportunity 
This report does not attempt to explore comprehensively 
all the issues that policy makers concerned with developing 
pharmaceutical care must take into account if they are to 
Box 4. The cost effectiveness of smoking 
cessation services
Compared with providing virtually all forms of curative 
and long term health and social care, the provision of 
smoking cessation services is highly cost effective. In 
England, for instance, Stapleton estimated (in 2001) that 
the then relatively new cessation services available there 
via community pharmacists and other providers generate 
additional life years for treated smokers aged 35-44 for 
just over £600 per life year gained. The equivalent figure 
for those aged 45-54 was £750.44 
Such figures are consistent with a cost per quality of life 
adjusted life year gained of in the order of £1,000. The 
UK National Institute for Health and Clinical Excellence’s 
operational limit on the affordability of additional 
quality of life adjusted life years for NHS treatments is 
by contrast about £30,000. Other sources15,29 also offer 
encouraging findings as to the cost effectiveness of both 
pharmacotherapies and pharmaceutical care for tobacco 
users in other European countries and the US, albeit that 
in some instances Qaly costs are significantly higher. 
In currently less affluent nations the relative costs 
of labour as opposed to medicines will differ. Given 
other priorities the case for publicly funded cessation 
support may not be as strong as it now is in the mature 
industrialised economies. But as national economies 
strengthen and wider public health measures begin to 
curb the smoking habit and restrict it to less advantaged 
groups, the case for individual level tobacco addiction 
treatment will become increasingly robust.
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enable the profession to play its full potential role in ending 
the global tobacco pandemic. Rather, three main themes are 
addressed here. They relate to the need to:
j  build pharmacists’ sense of self efficacy in relation to 
smoking cessation support, and their abilities to pro-
actively encourage pharmacy customers to address 
quitting;
j  resolve professional uncertainties about the safety and 
positive value of NRT and other medicines used to 
support quit attempts and tobacco use reduction; and
j  facilitate – through collective professional action 
and ethical partnerships with public agencies, the 
pharmaceutical industry and other groups – recognition 
of the growing global importance of smoking cessation 
support in tobacco control programmes.
Extending pharmacists’ competence and 
confidence
The international literature shows that many community 
pharmacists in the US, the UK and elsewhere say they feel 
qualified to provide tobacco cessation services. But there is also 
evidence that most do not routinely seek to identify smokers 
and act as first movers in opening dialogues with them about 
the possible benefits of quitting. This is vital for the provision 
of services with a significant public health impact. Pharmacists 
are currently much more likely to respond to smokers’ requests 
for advice than to initiate conversations about smoking habits 
and how they might be changed.
Even when NRT is being purchased, pharmacists may in 
many instances either be remote from the transaction or 
fail to communicate pro-actively with the customer about 
their experience with the product and how to use it to 
best effect. Making spontaneous interventions may be 
perceived by many pharmacists as being unduly invasive. 
There is also evidence that in, for example, the UK context, 
a proportion of pharmacists are – perhaps due to ingrained 
cultural assumptions – reluctant to take the initiative in 
communicating with GPs and asking them to refer potential 
quitters to the pharmacy for support. In parts of the world 
where there are higher numbers of doctors available, and 
there are less firmly established traditions of community 
and public health pharmacy, such problems may be even 
more acute.
However, specific education about tobacco cessation support 
can improve the quality and intensity of cessation counselling 
offered to patients. For example, a controlled study by 
Anderson (1995) showed that pharmacists who had received 
training were more likely to ask key questions, to use written 
information appropriately and/or when necessary (in the 
setting of that study) to refer to a medical practitioner.23 This 
and subsequent research suggests that pharmacy practice 
could be changed radically, and relatively easily. The key to 
achieving more effective patterns of pharmacy intervention 
may be raising the average pharmacist’s sense of self efficacy 
in relating to people, in addition to specifically facilitating 
the safe supply of pharmaceutical products. 
There is also limited research indicating that pharmacy 
assistants working in US and perhaps other settings may 
on occasions be better able to take the initiative in asking 
pharmacy users about their smoking habits than are 
pharmacists. It could therefore be argued that counter 
staff should be encouraged to make pro-active contact 
with potential quitters, and as necessary refer them on to 
a pharmacist or other suitable cessation services providers. 
However, too great a reliance on such a strategy could prove 
counter-productive, were it to draw attention away from 
the need to ensure that twenty first century pharmacists 
must have the confidence and skills needed for effective 
communication and clinical care delivery. 
From today’s perspective tobacco dependence shows many 
of the features characteristic of a chronic condition. Its 
alleviation may require sustained care and attention. More 
vulnerable tobacco users typically cycle through multiple 
periods of relapse and remission. Although a minority of 
tobacco users achieve permanent abstinence via a single quit 
attempt, others persist in tobacco use for many years after 
they first try to stop. 
By recognising that tobacco dependence often takes the form 
of a long term illness, pharmacists can better understand its 
nature and become more confident in meeting service user 
requirements for continuing, rather than fragmented episodic, 
support. This suggests that, from a professional development 
perspective, increased pharmacist involvement in smoking 
cessation support ought to prove a useful stepping stone 
to other forms of role extension. Arguably, the profession’s 
members will best be able to meet future ‘post transitional’ 
public requirements by enhancing their capacity to combine 
their knowledge of medicines with improved insight into 
medicine users’ psychological and social needs. This should 
enable them to facilitate health behaviour change, in order 
to support better patterns of medicine taking alongside other 
forms of health promotion and protection.
Resolving uncertainties and informing 
practice
Several respondents to The School of Pharmacy’s surveys 
mentioned concerns relating to the fact that NRT contains 
nicotine, the addictive component of tobacco smoke, rather 
than any other active ingredient. A proportion of pharmacists 
appear to fear that supplying NRT without careful professional 
control and counselling could do little or nothing to 
‘cure’ patients of their addiction, and may even be seen as 
undesirably perpetuating the latter. Others may be worried 
about safety. It appears that some believe that NRT could, 
for instance, harm people with cardio-vascular conditions 
or babies if it is used by women in pregnancy. It may also be 
thought that patients who use more than one type of NRT 
risk ‘overdosing’ on nicotine.
If unchecked, such dissonance could reinforce negative 
attitudes towards the provision of smoking cessation support 
services of all types, from the over-the-counter sale of 
appropriate aids through to more intensive support activities 
and other pharmacological treatments. Such a possibility 
emphasises the need for comprehensive, high quality, 
professional education that is kept updated throughout 
practitioners’ careers. There is in fact strong evidence that 
NRT use is in all circumstances safer than cigarette smoking. 
The UK Committee on Safety of Medicines has, for example, 
recently recommended45 that product information for all 
forms of NRT should not contra-indicate its use in:
j  pregnancy and lactation;
j  users with cardiovascular disease;
j  adolescents aged twelve to eighteen; and
j  circumstances which may lead to more than one form 
of NRT being used concurrently. 
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This and other authoritative sources also confirm that:
j  using NRT approximately doubles the chances of users 
stopping smoking, even when it is supplied without 
pharmacist or any other form of professional support. 
One relevant illustration of the research evidence 
supporting this observation is that an extensive US 
meta-analysis of the effectiveness of over-the-counter 
NRT supply found that it produced a quit rate of about 
seven per cent, which is comparable to the efficacy of 
NRT in real world prescription practice;46 and
j  there is a relatively low risk of long term NRT use.47 
However, even when this does occur it is likely to be 
associated with individual and public health benefits, 
because substituting tobacco smoking with NRT reduces 
unwanted health outcomes. This understanding is in part 
reflected in the fact that a ‘reduce to quit’ indication has 
been introduced in a range of European countries since 
1997. There is evidence that encouraging NRT use to 
cut down rather than stop smoking is likely in time to 
promote an increased number of quit attempts.
Although NRT products ought, like all other pharmaceuticals, 
to be used with appropriate caution (smokers with diabetes 
should, for instance, monitor their blood sugar more closely 
than usual when starting NRT use, and people with severely 
impaired liver or kidney function may be at an increased 
risk of side effects) they are relatively safe in use as compared 
with virtually any other form of medication or other legal 
(or illicit) drug taking. From a public health perspective all 
pharmacists should be aware of and willing to communicate 
such information, and offer similarly informed advice about 
other forms of pharmacologically active treatment for 
tobacco use. 
It might also be argued that pharmacy as a profession should 
also be able and willing to comment publicly on the (cost) 
effectiveness of other, non-pharmaceutical, approaches to 
smoking control and elimination. For example, it may be 
valuable to point out that the available evidence indicates 
that temporary financial incentives for quitting, such as those 
offered by ‘Quit and Win’ schemes, are ineffective in the 
medium to long term.48,49 They can encourage untruthful quit 
claims and when transient incentives end most quitters revert 
to their original behaviour. The most relevant implication of 
this research is that sustained behavioural changes need to be 
supported by genuine beliefs on the part of service users about 
what is in their best interests, rather than short term ‘bribes’ 
or other essentially coercive as opposed to professionally 
based approaches.
Forming effective public and private 
partnerships for smoking cessation 
Tobacco use, along with fatty food and sugar ingestion, has 
sometimes been perceived as fuelling industrial revolution, 
by helping workers to maintain concentration and energy 
levels. During the twentieth century the sale of tobacco 
products was often seen by governments as a public good. 
It provided employment, offered taxation opportunities and 
might have promoted satisfaction with – or at least increased 
public tolerance of – stressful social conditions. In poorer 
societies the fact that smoking can help control feelings of 
hunger may similarly appear to be beneficial.
Even in more affluent circumstances recognition of the fact 
that smoking kills has not always discouraged governments 
from condoning the use of cigarettes and allied products. For 
example, the British Treasury until quite recently seemed to 
regard the fact that smoking related deaths in early retirement 
reduce public expenditures on pensions as desirable. Given 
such observations, it is not surprising that in the past it 
was often left to doctors and other health professionals to 
spearhead efforts to persuade the public of the undesirability 
of smoking. 
However, as human societies develop their values tend to 
change in relation to not only factors such as the importance 
of exercising personal ‘consumer’ choice, but the importance 
of protecting health at a community wide level.50 Awareness 
of such global trends may today encourage governments and 
other agencies to support relatively early measures to curb the 
tobacco pandemic. For example, in China action is already 
being taken to implement the WHO Framework Convention 
on Tobacco Control. The relevant authorities are planning to 
require health warnings on all tobacco products by 2008, the 
year of the Beijing Olympics. Tobacco advertising should be 
banned across China by 2010.51
The opportunity that modern pharmacy could and arguably 
should grasp centres on the proven capacity of community 
based pharmacists to enhance the rate of successful stop 
Box 5. Safer nicotine?
Snus is a Swedish form of powdered tobacco. It is often 
referred to as an oral snuff, although it should not be 
confused with American and other fermented tobaccos 
sold for oral use. It is consumed by being placed behind 
the upper lip, rather than being ‘snorted’ or smoked, and 
is manufactured and stored in such a way as to minimise 
the formation of nitrosamines. The net result is that using 
snus may be up to 1,000 times less hazardous to health 
than cigarette smoking.52
Critics point to the fact that no form of smokeless tobacco 
can accurately said to be harmless, and that using snus 
habitually causes and/or sustains nicotine addiction. 
But proponents of a ‘safe nicotine’ approach argue that 
substituting snus use for smoking has helped to save lives 
in Sweden, and that the legitimate public health objective 
underlying tobacco control policies is the reduction of 
morbidity and premature mortality rates rather than the 
elimination of nicotine addiction per se.
Many alternative forms of tobacco use are highly 
hazardous, even when these do not involve combustion. 
In India, for instance, there are in addition to various 
local forms of smoked tobacco (such as beedis – sun 
dried tobacco rolled in a tendu leaf – and chuttas, a type 
of cheroot) a number of traditional smokeless tobacco 
products. Examples include paan with tobacco (plus 
ingredients like betel leaf, areca nut and slaked lime) and 
khaini (slaked lime and sun-dried tobacco). Traditional 
chewing and other smokeless tobaccos can be strongly 
carcinogenic. 
Generalised statements about the safety or otherwise 
of such products should therefore be avoided. Regional 
and community patterns of nicotine addiction and its 
desired and undesired consequences need to be rationally 
understood, in sociological and psychological as well as 
bio-medical terms. Effective tobacco control and harm 
reduction policies must also be based on clearly defined 
and publicly agreed aims. Although eliminating all forms 
of nicotine use might be considered an ideal goal, this 
may not always be practically achievable. 
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smoking attempts. A key finding of this report is that although 
individual and small group oriented programmes to ‘treat’ 
tobacco use are not in isolation likely to be as cost effective as 
traditional public health measures such as increasing tobacco 
product prices and introducing smoking bans, cessation 
services will become increasingly important towards the ‘end 
stage’ of the tobacco pandemic. International pharmacy is 
well placed to communicate this message, and take a leading 
part in defining the ways in which societies should tackle 
tobacco use addiction in those individuals, groups and 
communities that, for whatever reason, are slow to quit.
One possible option to be considered in this last context 
relates to extending access to ‘safe’ nicotine products designed 
for long term use. The example of snus (an unfermented 
oral snuff) use in Sweden indicates that benefits may stem 
from this type of approach (Box 5), despite disadvantages 
such as a raised oral cancer risk. However, it would not for 
the purposes of this report be appropriate to explore further 
such questions here. Rather, it is important to highlight 
the potential value of constructive partnerships between 
pharmacy and the medical profession, and between health 
professionals and health service user groups concerned with 
promoting smoking cessation. 
Appropriate collaborations between pharmacists and 
pharmaceutical companies that produce smoking cessation 
support products may also serve the public’s interest in 
enhancing access to effective smoking cessation, provided 
they are conducted in an ethical manner and are genuinely 
aimed at contributing to health improvement. The need for 
interest groups that are seeking to reduce, and ultimately 
eliminate, smoking to work together effectively is underlined 
by the enormous scale of both private and public investments 
in tobacco related industrial enterprises across the world. 
Counterbalancing resource asymmetries between the latter 
and agencies committed to reducing the harm caused by 
smoking will require intelligent co-operation and enterprise 
at all levels.
Conclusions and recommendations
Pharmacy has an important global role to play in helping to 
end the smoking pandemic. Tobacco use caused hundreds 
of millions of premature deaths in the twentieth century. 
Unchecked, it could inflict an even greater volume of harm 
in the next hundred years. Further development of the 
profession’s role in supporting smoking cessation at every 
level, from offering NRT and other medicines on an accessible 
over-the-counter basis to providing relatively intensive 
psychological support to potential quitters, could across the 
world promote high volumes of health gain at a cost which 
should become increasingly affordable.
In countries such as US, Denmark and Singapore there are 
already valuable examples of pharmacist supported smoking 
cessation services in place. In the case of the UK, this report 
has described relevant instances of successful pharmacy 
practice in Northern Ireland, Scotland and England. Wales 
too has made significant progress. Recommendations for 
further improvement in the context of British smoking 
cessation services range from increasing the scale and 
structural uniformity of smoking cessation programmes (in 
order to allow pharmacy groups of all sizes to use their staff 
in an optimally effective manner) to incorporating smoking 
behaviour assessments and follow up intervention planning 
in all pharmacist provided medication reviews.
The UK and wider EU and US experience also illustrates the 
importance of seeking to ensure that appropriate public and 
private systems are established to fund pharmacy based (and 
other) forms of smoking cessation support. However, it would 
be unfortunate if, in seeking to create appropriate financial 
environments for the delivery of enhanced pharmaceutical 
care, the impression were falsely given that the only thing 
that motivates the pharmaceutical profession’s members is 
money. This is not the case.
This report’s additional international recommendations are 
that:
j  Governments and other stakeholders in better public 
health (including pharmacy) should work globally to 
ensure that due emphasis is placed on smoking cessation 
service provision, via strong and comprehensive 
interpretations of Article 14 of the WHO’s Framework 
Convention for Tobacco Control; 
j  all health professionals should recognise the still 
growing importance of tobacco use as a threat to health 
world-wide, and work in partnership with other groups 
– including pharmaceutical industry and voluntary 
sector agencies – to promote smoking cessation along 
with other forms of tobacco control;
j  pharmacy leaders and regulators ought to encourage 
appropriate investments in professional training, to allow 
pharmacists to play a full and confident role in ending 
the global pandemic of tobacco related harm; and 
j  members of the public seeking to take a responsible 
approach to their own health and that of their 
families and communities should support public 
health programmes aimed at preventing smoking and 
(especially as tobacco use declines towards the point 
that it becomes in social terms a sickness rather than 
a normal habit) the provision of universally available 
services to help tobacco users free themselves of their 
life threatening condition.
Governments, health care professionals and citizens living in 
the mature industrial economies with long-term experience 
of tobacco related harm have a responsibility to share their 
smoking cessation service experience with communities that 
have not yet suffered the full health costs of mass tobacco 
use. The prize that this could lead to is an accelerated end to 
the global tobacco related harm pandemic, that could save 
tens or even hundreds of millions of premature deaths in 
the coming century.
Each community’s and nation’s developmental priorities 
must be respected. Yet in the final analysis the evidence is 
overwhelming that, in virtually all but the poorest of the 
modern world’s nations, tobacco smoking is normally the 
biggest single avoidable risk to health. Smoking cessation 
support is also one of the most cost effective of all possible 
health service investments. Hence helping individuals to 
stop smoking represents a vital opportunity, not only for 
pharmacy but for humanity world wide.
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Appendices Appendix I: United Kingdom Smoking Cessation Services Summary
Area Description Funding and infrastructure Economic Incentives
Outcomes
Recruitment Quit rate
Adur, Arun and 
Worthing
Pharmacists involved to a limited extent in 2 local areas. In one, 4 pharmacists have been trained to 
provide level 3 (specialist group cessation) services on a scheduled basis.  In the other, 2 pharmacies 
actively provide individual level 2 services in a 6 week scheme.  Clinic and GP clinics are main providers 
and pilot being carried out involving dental clinics.  Limited pharmacy involvement due to budget 
constraints but hope that in the near future it will be possible to have greater pharmacy input, especially 
from prescriber pharmacists.
NRT provided on GP’s 
prescription.  Training 
programme open to all 
pharmacists.
Flat remuneration rate regardless 
of success at 4 weeks (total fee 
approximately £55).
2355 set a quit date (SQD) 
in 05/06; Pop 210,000.
Pharmacies contribute 
about 1% of results (note 
that there are 45 GP clinics 
actively providing service).  
1517 (64%) quit at week 4 (QW4)
Camden Programme developed from joint Camden and Islington HAZ initiative, ‘pharmacy quitters’ now 
accounting for about one third of the total. Camden uses a fairly typical English NHS smoking cessation 
service specification, employing patient group directions (PGD) for NRT and allied produict supply and 
CO testing at four weeks
Supported by a co-
ordinator plus pharmacy 
lead.  Training programme 
available for pharmacists 
and assistants/dispensers. 
Total circa 50 pharmacies, 
of which c. 10% highly 
active
Payment to pharmacists totals 
£45 over 4 weeks for those 
administering PDG and providing 
support, starting with £15 for 
assessment. £10 for session 2 (quit 
date), £5 for 3&4 and £10 for 
session 5 (4 week follow up, CO 
test)
2857 SQD in 05/06;  
Pop 220,000.
1673 (59%) QW4.  
Charnwood 
and Northwest 
Leicestershire
Programme requires pharmacies to invest £300-£400 into the training of staff and equipment (eg, CO 
monitoring) before providing services.  
PCT budgets for service 
provision and training/
equipment costs have been 
pooled to provide greater 
economic incentive for 
service.   Pharmacies rather 
than the PCT are required 
to invest in service set 
up and are responsible 
for ongoing training of 
pharmacists and equipment 
maintenance.
Pharmacies paid £25 per quit 
attempt and £50 per successful 
quitter (currently reduced to £40 
due to budget restrictions).
Pharmacies see economic need to 
provide service in order to recoup 
investment and hence greater buy 
in.
2247 SQD in 05/06; 
Pop 230,000.   
1632 (73%) QW4.
Croydon ‘Charismatic’ pharmacy leadership appears to helped senior PCT management to understand that 
community pharmacy has the potential to deliver performance targets. There are relatively high local 
levels of pharmacy payment.
Training and support 
provided. However, 
only about 10 out of 70 
pharmacies judged fully 
active in the delivery of 
cessation support.
Payment to pharmacists totals £90, 
including £45 for the initial ‘work 
up’ and £10 final monitoring 
payment.
3324 SQD in 05/06;  
Pop 340,000.
1454 (44%) QW4.
Glasgow and 
Clyde
‘Starting Fresh’ initiative: 12 week programme.  207 (94%) pharmacies involved.  Quiet area is required 
to provide service.  Pharmacist prescribes NRT according to Glasgow Formulary guidelines.  After 
initial interview, either pharmacist or assistant can see the customer.  Customer agrees to attend the 
pharmacy on a weekly basis for NRT and counselling.  CO levels measured.  Nicorette® 16 hour patch is 
formulation of choice.  Support groups also set up – NRT supplied from week 3 of quit attempt.  
There has been an overall downturn in GP prescribing costs of NRT since introduction of programme 
(absolute decrease of 13% between 2005 – 2006).   
NRT reimbursed by NHS, 
usual prescription charge to 
customer.  One day training 
for brief negotiation 
interventions and distance 
learning pack on NRT (need 
to pass with 80%) given to 
pharmacists and assistants.  
Pharmacies paid £30 per customer 
enrolled (or £15 if recruited from 
the group smoking cessation 
programme).  Paid £5 even if 
customer fails to return after week 
1.  
More than 42,000 smokers 
recruited over 3 years.  
On average 1000 new 
customers register for 
service each month.
Quit rates:
5 -12 weeks 
• 29-39% for pharmacy 
recruited customers
• 38-52% for group recruited 
customers. 
12 – 52 weeks
• 12-18% (pharmacy) 
• 14-30% (group).  
After 52 weeks
• 4-8% (pharmacy) 
• 5-14% (group).  
There appears to be an 
association between deprivation 
status and quit rate.
Greenwich 4 week NRT scheme.  35 pharmacies involved, all have private consultation space. Free NRT patches 
promotion scheme 
has been successful in 
encouraging people 
to access services in 
pharmacies.
Pharmacies paid £40 for a 
successful quit; and £10 - £25 
(depending on length of follow 
up) for unsuccessful quit.  
2770 SQD in 05/06; 
Pop 230,000.
Pharmacy contributes 
around 50% of results.
1286 (46%) QW4.  
Haringey 4 week scheme.  48/55 pharmacies in the area provide services, but “only a handful of trained 
pharmacists have provided services to the expected level.”  
60 pharmacists trained; 
only 5/55 pharmacies 
considered active.
Basic pharmacy payments total 
£45. Experiment with £70 
payment per successful quitter 
but no payment for failed 
interventions did not motivate 
pharmacists, but positive response 
from practice nurses.
4006 SQD in 05/06; 
Pop 230,000
2815 (70%) QW4.  
Harrow 5 week scheme.  52/54 pharmacies delivering the service.  Programme offers counselling and 
motivational support, CO monitoring and prescriptions through a PGD for NRT.  
NRT supplied through 
PGD.  Initial training plus 
regular top up training 
every 6 months offered 
(compulsory).
Pharmacies paid according to 
staggered payment structure 
– initial pre-assessment £15, 
first appointment £15, next 
3 appointments £5 and final 
appointment £15 (£60 per quit).  
2578 SQD in 05/06;
Pop 200,000
1186 (46%) QW4  in 2005/06.   
2007 quit rate 45%.  
Target for 2005/2007 – 1252 
quitters.  
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Area Description Funding and infrastructure Economic Incentives
Outcomes
Recruitment Quit rate
Adur, Arun and 
Worthing
Pharmacists involved to a limited extent in 2 local areas. In one, 4 pharmacists have been trained to 
provide level 3 (specialist group cessation) services on a scheduled basis.  In the other, 2 pharmacies 
actively provide individual level 2 services in a 6 week scheme.  Clinic and GP clinics are main providers 
and pilot being carried out involving dental clinics.  Limited pharmacy involvement due to budget 
constraints but hope that in the near future it will be possible to have greater pharmacy input, especially 
from prescriber pharmacists.
NRT provided on GP’s 
prescription.  Training 
programme open to all 
pharmacists.
Flat remuneration rate regardless 
of success at 4 weeks (total fee 
approximately £55).
2355 set a quit date (SQD) 
in 05/06; Pop 210,000.
Pharmacies contribute 
about 1% of results (note 
that there are 45 GP clinics 
actively providing service).  
1517 (64%) quit at week 4 (QW4)
Camden Programme developed from joint Camden and Islington HAZ initiative, ‘pharmacy quitters’ now 
accounting for about one third of the total. Camden uses a fairly typical English NHS smoking cessation 
service specification, employing patient group directions (PGD) for NRT and allied produict supply and 
CO testing at four weeks
Supported by a co-
ordinator plus pharmacy 
lead.  Training programme 
available for pharmacists 
and assistants/dispensers. 
Total circa 50 pharmacies, 
of which c. 10% highly 
active
Payment to pharmacists totals 
£45 over 4 weeks for those 
administering PDG and providing 
support, starting with £15 for 
assessment. £10 for session 2 (quit 
date), £5 for 3&4 and £10 for 
session 5 (4 week follow up, CO 
test)
2857 SQD in 05/06;  
Pop 220,000.
1673 (59%) QW4.  
Charnwood 
and Northwest 
Leicestershire
Programme requires pharmacies to invest £300-£400 into the training of staff and equipment (eg, CO 
monitoring) before providing services.  
PCT budgets for service 
provision and training/
equipment costs have been 
pooled to provide greater 
economic incentive for 
service.   Pharmacies rather 
than the PCT are required 
to invest in service set 
up and are responsible 
for ongoing training of 
pharmacists and equipment 
maintenance.
Pharmacies paid £25 per quit 
attempt and £50 per successful 
quitter (currently reduced to £40 
due to budget restrictions).
Pharmacies see economic need to 
provide service in order to recoup 
investment and hence greater buy 
in.
2247 SQD in 05/06; 
Pop 230,000.   
1632 (73%) QW4.
Croydon ‘Charismatic’ pharmacy leadership appears to helped senior PCT management to understand that 
community pharmacy has the potential to deliver performance targets. There are relatively high local 
levels of pharmacy payment.
Training and support 
provided. However, 
only about 10 out of 70 
pharmacies judged fully 
active in the delivery of 
cessation support.
Payment to pharmacists totals £90, 
including £45 for the initial ‘work 
up’ and £10 final monitoring 
payment.
3324 SQD in 05/06;  
Pop 340,000.
1454 (44%) QW4.
Glasgow and 
Clyde
‘Starting Fresh’ initiative: 12 week programme.  207 (94%) pharmacies involved.  Quiet area is required 
to provide service.  Pharmacist prescribes NRT according to Glasgow Formulary guidelines.  After 
initial interview, either pharmacist or assistant can see the customer.  Customer agrees to attend the 
pharmacy on a weekly basis for NRT and counselling.  CO levels measured.  Nicorette® 16 hour patch is 
formulation of choice.  Support groups also set up – NRT supplied from week 3 of quit attempt.  
There has been an overall downturn in GP prescribing costs of NRT since introduction of programme 
(absolute decrease of 13% between 2005 – 2006).   
NRT reimbursed by NHS, 
usual prescription charge to 
customer.  One day training 
for brief negotiation 
interventions and distance 
learning pack on NRT (need 
to pass with 80%) given to 
pharmacists and assistants.  
Pharmacies paid £30 per customer 
enrolled (or £15 if recruited from 
the group smoking cessation 
programme).  Paid £5 even if 
customer fails to return after week 
1.  
More than 42,000 smokers 
recruited over 3 years.  
On average 1000 new 
customers register for 
service each month.
Quit rates:
5 -12 weeks 
• 29-39% for pharmacy 
recruited customers
• 38-52% for group recruited 
customers. 
12 – 52 weeks
• 12-18% (pharmacy) 
• 14-30% (group).  
After 52 weeks
• 4-8% (pharmacy) 
• 5-14% (group).  
There appears to be an 
association between deprivation 
status and quit rate.
Greenwich 4 week NRT scheme.  35 pharmacies involved, all have private consultation space. Free NRT patches 
promotion scheme 
has been successful in 
encouraging people 
to access services in 
pharmacies.
Pharmacies paid £40 for a 
successful quit; and £10 - £25 
(depending on length of follow 
up) for unsuccessful quit.  
2770 SQD in 05/06; 
Pop 230,000.
Pharmacy contributes 
around 50% of results.
1286 (46%) QW4.  
Haringey 4 week scheme.  48/55 pharmacies in the area provide services, but “only a handful of trained 
pharmacists have provided services to the expected level.”  
60 pharmacists trained; 
only 5/55 pharmacies 
considered active.
Basic pharmacy payments total 
£45. Experiment with £70 
payment per successful quitter 
but no payment for failed 
interventions did not motivate 
pharmacists, but positive response 
from practice nurses.
4006 SQD in 05/06; 
Pop 230,000
2815 (70%) QW4.  
Harrow 5 week scheme.  52/54 pharmacies delivering the service.  Programme offers counselling and 
motivational support, CO monitoring and prescriptions through a PGD for NRT.  
NRT supplied through 
PGD.  Initial training plus 
regular top up training 
every 6 months offered 
(compulsory).
Pharmacies paid according to 
staggered payment structure 
– initial pre-assessment £15, 
first appointment £15, next 
3 appointments £5 and final 
appointment £15 (£60 per quit).  
2578 SQD in 05/06;
Pop 200,000
1186 (46%) QW4  in 2005/06.   
2007 quit rate 45%.  
Target for 2005/2007 – 1252 
quitters.  
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Area Description Funding and infrastructure Economic Incentives
Outcomes
Recruitment Quit rate
Islington 4 week scheme.  37/45 pharmacies involved.  Scheme established in 1999. Model similar to that of 
Camden, derived from common HAZ experience. Strong local focus on the potential value of community 
pharmacy contributions to meeting cessation goals. Both boroughs have high deprivation rates and large 
ethnic minority groups, but also significant affluent populations. 
PGD for NRT.  Stop 
smoking training 
recognised as part of CPD 
for pharmacists in new 
agreement.  
Pharmacies paid £45 for a 
successful quit and £35 for an 
unsuccessful quit.  
3569 SQD in 05/06; 
Pop< 180,000.
1939 (54%) QW4. Approximately 
35% of these were through 
pharmacies.
Middlesbrough 3 month scheme. Pharmacists are an integral part of services in PCT.  Two schemes operate, one 
described as a voucher scheme and the other is a ‘one-stop-shop’.  
• Voucher scheme: first assessment done at stop smoking clinic with follow up for 4 weeks, if remain 
smoke free they return to the clinic for an 8 week follow up voucher through pharmacy.  
• One-stop-shop: direct access of stop smoking service at pharmacy for 3 month period. 
Most pharmacies in PCT 
involved in providing 
service.  NRT given with 
usual prescription charge.  
Specialist and call services 
also provided by other 
health professionals.
Good communication 
between clinic and 
pharmacies felt to 
contribute to success of 
scheme.
Payment for service of 4 weeks or 
3 months.  £10 bonus given for 
successful quit at 4 weeks.  
3953 SQD in 05/06;  
Pop < 200,000.  
1779 (45%) QW4 in 2005/06. 
61% of these were through 
pharmacies.
Newcastle and 
North Tyneside
4 week scheme.  Service running with pharmacies for 6 years.  50 pharmacies delivering service and more 
have taken up service with time (especially with the new pharmacy contract).    
Agreements signed with 
chains and individual 
pharmacies.  NRT supplied 
on PGD; NRT charged 
at prescription costs and 
reimbursed by PCT.  Service 
providers have good support 
from PCT and receive 
promotional materials 
and regular updates.  Free 
training provided to 
pharmacists and pharmacy 
technicians/ assistants.
Pharmacies paid £10 for drop out 
customers and £20 for quitters or 
those who remain in programme 
at 4 weeks. 
Newcastle reported 4854 
SQD in 05/06; Pop 270,000.
N Tyneside 3882 SQD in 
05/06; Pop 200,000.
Pharmacy data represents 
around 19-20% of total 
data received on smoking 
cessation services in the 
PCTs.
Newcastle: 2342 (48%) QW4.
North Tyneside 1907 (49%) 
QW4.
Northern Ireland 4 week scheme with check up at 52 weeks.  Current model introduced December 2006. Pharmacy 
involvement supported by charismatic local leadership. Scheme now nationwide, replacing previous 
arrangements that were delivered independently via the four NI Health and Social Service Boards.
Additional funding 
provided for nationally 
to enable pharmacy to 
provide NRT directly 
– might be seen as a step 
towards a pharmacy 
prescribing budget.
Pharmacies paid a flat rate 4 week 
course payment of £28 per patient/
user regardless of whether or not a 
successful quit is recorded, coupled 
with an additional £7 for a 52 
week cessation monitoring check.
Figures for 2002/03 
indicate a national total of 
circa 9,000 setting a quit 
date. Total NI population 
1.7 million.
60 per cent of professionals 
delivering smoking 
cessation services were 
pharmacists in 2003
Self report success rate 58 per 
cent at four weeks in 2003, 
dropping to 47 per cent where 
non-smoking status was 
confirmed by CO validation.
North Tees, 
Hartlepool, 
Redcar and 
Cleveland
Pharmacists not actively involved in services apart from 2 pharmacies which were involved in a trial.  
Limited involvement as there is not payment scheme for pharmacists to provide services in the PCT.  
Stop smoking services mainly provided through clinic and prescriber nurses.
Potential for future development though steps for greater involvement not taken yet.  Would prefer to 
target prescriber pharmacists and involve selected pharmacies through voucher scheme.
Training is open to all 
pharmacists to participate
North Tees 3229 SQD in 
05/06; Pop 180,000.
Hartlepool 2564 SQD in 
05/06; Pop 90,000.
Around 10% of results 
come through the 2 
pharmacies that do provide 
the service.
North Tees 1551 (48%) QW4.  
Hartlepool 1328 (52%) QW4.  
Richmond and 
Twickenham
6 week scheme.  Pharmacists are actively involved in scheme.  85% of pharmacists trained in Richmond 
and Twickenham area, 75% of pharmacists trained in Kingston area.
2 week prescriptions given 
for NRT by GPs upon 
advice of pharmacist 
and charged at usual 
prescription cost.
Pharmacies paid as a staggered rate 
with £20 for first visit and £10 for 
each visit thereafter.  £5 bonus for 
successful quit.  
1204 SQD in 05/06;  
Pop 180,000.
Pharmacy data represents 
around 50% of total results.
568 QW4.  
• 47% through PCT.
• 55% through pharmacies.
Yorkshire, Wolds 
and Coast; Hull 
and East Riding
6 week scheme.  Limited involvement of pharmacists.  1 scheme in Hull involving 6 pharmacies that 
agreed to take part in a pilot in 2005.  There is an agreed maximum number of clients that are able to use 
the pharmacy service per year (approximately 20-50 per pharmacy). Capped involvement due to budget 
restraints.  One community pharmacy actively provides service in Yorkshire Wolds and Coast. This is 
seen as a cost effective way of enabling access to cessation services in a small and in modern UK terms  
isolated community.
Voucher scheme also exists 
for NRT to be dispensed 
at pharmacies (pharmacy 
paid a £3 dispensing fee) 
with payment of usual 
prescription cost.  This 
supports the specialist 
(level 3) smoking cessation 
support model relatively 
widely employed in these 
localities.
Flat remuneration regardless of 
quit success. Total £39, comprising 
three payments of £10 and three of 
£3 in the 2005/06 model described 
here.
Eastern Hull reported 1421 
SQD in 05/06; 
Pop 120,000.
West Hull reported 1736 
SQD in 05/06;  
Pop 150,000.
Yorkshire, Wolds and Coast 
reported 1127 SQD in 
05/06;  Pop 150,000.
Quit rate through pharmacy is 
lower than main stop smoking 
services.  An evaluation of reason 
for lower success rate is needed 
before considering expansion of 
scheme.
Eastern Hull 982 Q4W.  
West Hull 1190 Q4W.  
Yorkshire, Wolds and Coast 779 
Q4W.
69% quit at 4 weeks in all PCTs.
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Area Description Funding and infrastructure Economic Incentives
Outcomes
Recruitment Quit rate
Islington 4 week scheme.  37/45 pharmacies involved.  Scheme established in 1999. Model similar to that of 
Camden, derived from common HAZ experience. Strong local focus on the potential value of community 
pharmacy contributions to meeting cessation goals. Both boroughs have high deprivation rates and large 
ethnic minority groups, but also significant affluent populations. 
PGD for NRT.  Stop 
smoking training 
recognised as part of CPD 
for pharmacists in new 
agreement.  
Pharmacies paid £45 for a 
successful quit and £35 for an 
unsuccessful quit.  
3569 SQD in 05/06; 
Pop< 180,000.
1939 (54%) QW4. Approximately 
35% of these were through 
pharmacies.
Middlesbrough 3 month scheme. Pharmacists are an integral part of services in PCT.  Two schemes operate, one 
described as a voucher scheme and the other is a ‘one-stop-shop’.  
• Voucher scheme: first assessment done at stop smoking clinic with follow up for 4 weeks, if remain 
smoke free they return to the clinic for an 8 week follow up voucher through pharmacy.  
• One-stop-shop: direct access of stop smoking service at pharmacy for 3 month period. 
Most pharmacies in PCT 
involved in providing 
service.  NRT given with 
usual prescription charge.  
Specialist and call services 
also provided by other 
health professionals.
Good communication 
between clinic and 
pharmacies felt to 
contribute to success of 
scheme.
Payment for service of 4 weeks or 
3 months.  £10 bonus given for 
successful quit at 4 weeks.  
3953 SQD in 05/06;  
Pop < 200,000.  
1779 (45%) QW4 in 2005/06. 
61% of these were through 
pharmacies.
Newcastle and 
North Tyneside
4 week scheme.  Service running with pharmacies for 6 years.  50 pharmacies delivering service and more 
have taken up service with time (especially with the new pharmacy contract).    
Agreements signed with 
chains and individual 
pharmacies.  NRT supplied 
on PGD; NRT charged 
at prescription costs and 
reimbursed by PCT.  Service 
providers have good support 
from PCT and receive 
promotional materials 
and regular updates.  Free 
training provided to 
pharmacists and pharmacy 
technicians/ assistants.
Pharmacies paid £10 for drop out 
customers and £20 for quitters or 
those who remain in programme 
at 4 weeks. 
Newcastle reported 4854 
SQD in 05/06; Pop 270,000.
N Tyneside 3882 SQD in 
05/06; Pop 200,000.
Pharmacy data represents 
around 19-20% of total 
data received on smoking 
cessation services in the 
PCTs.
Newcastle: 2342 (48%) QW4.
North Tyneside 1907 (49%) 
QW4.
Northern Ireland 4 week scheme with check up at 52 weeks.  Current model introduced December 2006. Pharmacy 
involvement supported by charismatic local leadership. Scheme now nationwide, replacing previous 
arrangements that were delivered independently via the four NI Health and Social Service Boards.
Additional funding 
provided for nationally 
to enable pharmacy to 
provide NRT directly 
– might be seen as a step 
towards a pharmacy 
prescribing budget.
Pharmacies paid a flat rate 4 week 
course payment of £28 per patient/
user regardless of whether or not a 
successful quit is recorded, coupled 
with an additional £7 for a 52 
week cessation monitoring check.
Figures for 2002/03 
indicate a national total of 
circa 9,000 setting a quit 
date. Total NI population 
1.7 million.
60 per cent of professionals 
delivering smoking 
cessation services were 
pharmacists in 2003
Self report success rate 58 per 
cent at four weeks in 2003, 
dropping to 47 per cent where 
non-smoking status was 
confirmed by CO validation.
North Tees, 
Hartlepool, 
Redcar and 
Cleveland
Pharmacists not actively involved in services apart from 2 pharmacies which were involved in a trial.  
Limited involvement as there is not payment scheme for pharmacists to provide services in the PCT.  
Stop smoking services mainly provided through clinic and prescriber nurses.
Potential for future development though steps for greater involvement not taken yet.  Would prefer to 
target prescriber pharmacists and involve selected pharmacies through voucher scheme.
Training is open to all 
pharmacists to participate
North Tees 3229 SQD in 
05/06; Pop 180,000.
Hartlepool 2564 SQD in 
05/06; Pop 90,000.
Around 10% of results 
come through the 2 
pharmacies that do provide 
the service.
North Tees 1551 (48%) QW4.  
Hartlepool 1328 (52%) QW4.  
Richmond and 
Twickenham
6 week scheme.  Pharmacists are actively involved in scheme.  85% of pharmacists trained in Richmond 
and Twickenham area, 75% of pharmacists trained in Kingston area.
2 week prescriptions given 
for NRT by GPs upon 
advice of pharmacist 
and charged at usual 
prescription cost.
Pharmacies paid as a staggered rate 
with £20 for first visit and £10 for 
each visit thereafter.  £5 bonus for 
successful quit.  
1204 SQD in 05/06;  
Pop 180,000.
Pharmacy data represents 
around 50% of total results.
568 QW4.  
• 47% through PCT.
• 55% through pharmacies.
Yorkshire, Wolds 
and Coast; Hull 
and East Riding
6 week scheme.  Limited involvement of pharmacists.  1 scheme in Hull involving 6 pharmacies that 
agreed to take part in a pilot in 2005.  There is an agreed maximum number of clients that are able to use 
the pharmacy service per year (approximately 20-50 per pharmacy). Capped involvement due to budget 
restraints.  One community pharmacy actively provides service in Yorkshire Wolds and Coast. This is 
seen as a cost effective way of enabling access to cessation services in a small and in modern UK terms  
isolated community.
Voucher scheme also exists 
for NRT to be dispensed 
at pharmacies (pharmacy 
paid a £3 dispensing fee) 
with payment of usual 
prescription cost.  This 
supports the specialist 
(level 3) smoking cessation 
support model relatively 
widely employed in these 
localities.
Flat remuneration regardless of 
quit success. Total £39, comprising 
three payments of £10 and three of 
£3 in the 2005/06 model described 
here.
Eastern Hull reported 1421 
SQD in 05/06; 
Pop 120,000.
West Hull reported 1736 
SQD in 05/06;  
Pop 150,000.
Yorkshire, Wolds and Coast 
reported 1127 SQD in 
05/06;  Pop 150,000.
Quit rate through pharmacy is 
lower than main stop smoking 
services.  An evaluation of reason 
for lower success rate is needed 
before considering expansion of 
scheme.
Eastern Hull 982 Q4W.  
West Hull 1190 Q4W.  
Yorkshire, Wolds and Coast 779 
Q4W.
69% quit at 4 weeks in all PCTs.
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Appendix II: International Smoking Cessation Services Summary
Country Tobacco cessation activity
Economic 
incentives
Other
incentives
Infrastructure 
and support
Awareness and 
promotion
Education and 
training Outcomes Policies Comments and future plans
Australia
Adult smoking:
21% male
18% female
1,907 cigarette 
consumption 
annual pp
Pharmacy guild 
commissioned two 
projects – 2004, 2006.
2004: SUPPORTU project 
aimed to examine 
effectiveness of smoking 
cessation services delivered 
by community pharmacy. 
18 months, 80 pharmacies 
recruited.  5A Smoking 
cessation framework 
adopted.  Pharmacies were 
to recruit customers and 
refer them to Quitline 
program or provide formal 
smoking cessation support.
2006: Pharmacy smoking 
cessation project.  Built 
on pilot from 2002 with 
$1million AUD funding.  
Aimed to implement an 
effective quit smoking 
management program.  6 
months, 400 pharmacies.
None Materials provided 
by pharmacy guild 
– stands, brochures, 
passports, Dr’s 
referral pad.  
Wide publicity 
campaign using all 
media.
Training provided to 
pharmacists.
2004: as part of 
SUPPORTU - introductory 
workshop, academic 
detailing visits, mystery 
shopper visits and 
feedback and staff 
meetings.
2006: Online training 
provided through the 
Centre for Innovation 
in Health Professional 
Health Education, 
University of Sydney 
– developed an 
online course.  More 
comprehensive course for 
assistants and a refresher 
course for pharmacists.  
2004: SUPPORTU project 
- 107 smokers referred/ 
88 smokers enrolled 
into support programme 
in 6 months.   70% of 
intervention pharmacists 
discussed importance of 
support from Quitline vs. 
29% in control.     
19% intervention 
pharmacists enrolled mystery 
shopper into pharmacy 
team support vs 3% control.  
NRT sales increased in both 
groups.  
2006: 792 customer survey 
forms returned over 6 
months.  55% of control and 
intervention respondents 
remained quit at 12 weeks.  
Outcome evaluation showed 
no statistically significant 
effect of intervention over 
control group.  NRT sales 
actually marginally decreased 
over intervention period 
compared to baseline.  52% 
customers of intervention 
group quit after 6 months, 
while 48% quit from control 
group.
NRT available as general 
sale since March 2006.  No 
government/state funding 
for services in Community 
Pharmacy Agreement.  
Following SUPPORTU: recommendations 
included incorporating smoking cessation 
advice as an integral part of the role of 
accredited pharmacists when undertaking 
Home Medicines Review, smoking 
cessation training should be a required 
and accredited role, funding should be 
sought in negotiations for pharmacy/
government agreement for support of 
pharmacies, and that payment for services 
should be a yearly practice incentive 
allowance.
2006 project:  Customers attending 
intervention pharmacies were more 
inclined to speak to pharmacy assistants 
in addition to pharmacists and receive 
more useful advice and support than in 
control pharmacies.  Concluded that the 
process indicators of intervention impact 
are positive and result in significant 
impact on outcomes relating to pharmacy 
(as opposed to impact on smokers) 
– increased positive regard for pharmacy 
and likelihood of repeat purchase from 
the same pharmacy.  However stated that 
intervention NRT buyers were more likely 
to receive useful advice, be informed of 
support services and complete the NRT 
program.
Canada
Adult smoking:
27% male
23% female
1,976 cigarette 
consumption 
annual pp
No national program but 
largest provincial program 
is Clinical Tobacco 
Intervention (CTI), co-
sponsored by Dental, 
Medical and Pharmacy 
Societies in Ontario and 
the Canadian Medical 
Association.
No national 
reimbursement 
system but 
one-off reports 
of pharmacists 
charging 
patients.  
Recent 
(unpublished) 
pilot by Green 
Shield Canada 
to pay for 
products + 
pharmacy 
services.
CTI provides 
training & support 
materials.  Website 
is www.ctica.org
CTI trains dentists, 
physicians, 
pharmacists, nurses 
and support staff 
together.
> 3500 clinicians trained by 
CTI (requests for training 
increased recently because 
required for reimbursement 
in Green Shield pilot).
NRT recently moved from 
pharmacy-only sales to 
general sale.
Ontario Drug Benefit 
(ODB) Program does not 
pay for NRT products.
New legislation in Ontario for 2007 will 
pay for some cognitive services through 
ODB; possibly smoking cessation.
1-2 provinces in Canada still sell tobacco 
products in pharmacies.
SW Ontario still produces some tobacco.
Stop Smoking for Ontario Patients (STOP) 
study is currently looking at outcomes of 
providing free NRT (via mass mail & via 
clinicians) to 14,000 smokers.
Denmark
Adult smoking:
32% male
29% female
1,919 cigarette 
consumption 
annual pp
National pharmacy 
program commenced in 
1986.  
Pharmacy programs 
provided in 10 of the 
14 counties in Denmark 
until 2007.  Negotiations 
currently underway to re-
establish services amongst 
the newly formed 150 
municipalities.
Services provided free 
of charge or in range 
of 50-100% subsidy for 
customers.
New brief consultation 
service.
Danish 
pharmacies 
allocated 3 
million kroner 
per year for 
2005-2008.  
Funding spent 
on increasing 
access, 
information 
campaigns, new 
services.
Pharmacy 
remunerated 
around 170 
Euros for every 
customer that 
completes the 
programme and 
is followed up 
on at 52 weeks.
Smoking cessation 
brochure translated 
into 7 languages for 
ethnic minorities.
Campaigns to 
inform general 
practitioners of 
programs.  53% 
of respondents 
stated they would 
go to a pharmacist 
if recommended 
by doctor.  Many 
doctors don’t 
recommend service 
as little is known 
about it.
Training provided-based 
on materials and models 
produced in partnership 
with the Cancer Society.  
11 pharmacists from 
ethnic minorities 
are also trained to 
provide services to this 
population group.  
Quit rate is 30% at 52 weeks.
Brief consultation service 
tested in 25 pharmacies.  145 
pharmacies offer individual 
smoking cessation services, 
151 pharmacies offer group 
services.
NRT not covered in 
funded/subsidised 
schemes.
Cooperation with national state will end 
in 2007 and be replaced with municipal 
based cooperation.
Future programs will target pregnant 
smokers and those with diabetes and heart 
disease.
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Economic 
incentives
Other
incentives
Infrastructure 
and support
Awareness and 
promotion
Education and 
training Outcomes Policies Comments and future plans
Australia
Adult smoking:
21% male
18% female
1,907 cigarette 
consumption 
annual pp
Pharmacy guild 
commissioned two 
projects – 2004, 2006.
2004: SUPPORTU project 
aimed to examine 
effectiveness of smoking 
cessation services delivered 
by community pharmacy. 
18 months, 80 pharmacies 
recruited.  5A Smoking 
cessation framework 
adopted.  Pharmacies were 
to recruit customers and 
refer them to Quitline 
program or provide formal 
smoking cessation support.
2006: Pharmacy smoking 
cessation project.  Built 
on pilot from 2002 with 
$1million AUD funding.  
Aimed to implement an 
effective quit smoking 
management program.  6 
months, 400 pharmacies.
None Materials provided 
by pharmacy guild 
– stands, brochures, 
passports, Dr’s 
referral pad.  
Wide publicity 
campaign using all 
media.
Training provided to 
pharmacists.
2004: as part of 
SUPPORTU - introductory 
workshop, academic 
detailing visits, mystery 
shopper visits and 
feedback and staff 
meetings.
2006: Online training 
provided through the 
Centre for Innovation 
in Health Professional 
Health Education, 
University of Sydney 
– developed an 
online course.  More 
comprehensive course for 
assistants and a refresher 
course for pharmacists.  
2004: SUPPORTU project 
- 107 smokers referred/ 
88 smokers enrolled 
into support programme 
in 6 months.   70% of 
intervention pharmacists 
discussed importance of 
support from Quitline vs. 
29% in control.     
19% intervention 
pharmacists enrolled mystery 
shopper into pharmacy 
team support vs 3% control.  
NRT sales increased in both 
groups.  
2006: 792 customer survey 
forms returned over 6 
months.  55% of control and 
intervention respondents 
remained quit at 12 weeks.  
Outcome evaluation showed 
no statistically significant 
effect of intervention over 
control group.  NRT sales 
actually marginally decreased 
over intervention period 
compared to baseline.  52% 
customers of intervention 
group quit after 6 months, 
while 48% quit from control 
group.
NRT available as general 
sale since March 2006.  No 
government/state funding 
for services in Community 
Pharmacy Agreement.  
Following SUPPORTU: recommendations 
included incorporating smoking cessation 
advice as an integral part of the role of 
accredited pharmacists when undertaking 
Home Medicines Review, smoking 
cessation training should be a required 
and accredited role, funding should be 
sought in negotiations for pharmacy/
government agreement for support of 
pharmacies, and that payment for services 
should be a yearly practice incentive 
allowance.
2006 project:  Customers attending 
intervention pharmacies were more 
inclined to speak to pharmacy assistants 
in addition to pharmacists and receive 
more useful advice and support than in 
control pharmacies.  Concluded that the 
process indicators of intervention impact 
are positive and result in significant 
impact on outcomes relating to pharmacy 
(as opposed to impact on smokers) 
– increased positive regard for pharmacy 
and likelihood of repeat purchase from 
the same pharmacy.  However stated that 
intervention NRT buyers were more likely 
to receive useful advice, be informed of 
support services and complete the NRT 
program.
Canada
Adult smoking:
27% male
23% female
1,976 cigarette 
consumption 
annual pp
No national program but 
largest provincial program 
is Clinical Tobacco 
Intervention (CTI), co-
sponsored by Dental, 
Medical and Pharmacy 
Societies in Ontario and 
the Canadian Medical 
Association.
No national 
reimbursement 
system but 
one-off reports 
of pharmacists 
charging 
patients.  
Recent 
(unpublished) 
pilot by Green 
Shield Canada 
to pay for 
products + 
pharmacy 
services.
CTI provides 
training & support 
materials.  Website 
is www.ctica.org
CTI trains dentists, 
physicians, 
pharmacists, nurses 
and support staff 
together.
> 3500 clinicians trained by 
CTI (requests for training 
increased recently because 
required for reimbursement 
in Green Shield pilot).
NRT recently moved from 
pharmacy-only sales to 
general sale.
Ontario Drug Benefit 
(ODB) Program does not 
pay for NRT products.
New legislation in Ontario for 2007 will 
pay for some cognitive services through 
ODB; possibly smoking cessation.
1-2 provinces in Canada still sell tobacco 
products in pharmacies.
SW Ontario still produces some tobacco.
Stop Smoking for Ontario Patients (STOP) 
study is currently looking at outcomes of 
providing free NRT (via mass mail & via 
clinicians) to 14,000 smokers.
Denmark
Adult smoking:
32% male
29% female
1,919 cigarette 
consumption 
annual pp
National pharmacy 
program commenced in 
1986.  
Pharmacy programs 
provided in 10 of the 
14 counties in Denmark 
until 2007.  Negotiations 
currently underway to re-
establish services amongst 
the newly formed 150 
municipalities.
Services provided free 
of charge or in range 
of 50-100% subsidy for 
customers.
New brief consultation 
service.
Danish 
pharmacies 
allocated 3 
million kroner 
per year for 
2005-2008.  
Funding spent 
on increasing 
access, 
information 
campaigns, new 
services.
Pharmacy 
remunerated 
around 170 
Euros for every 
customer that 
completes the 
programme and 
is followed up 
on at 52 weeks.
Smoking cessation 
brochure translated 
into 7 languages for 
ethnic minorities.
Campaigns to 
inform general 
practitioners of 
programs.  53% 
of respondents 
stated they would 
go to a pharmacist 
if recommended 
by doctor.  Many 
doctors don’t 
recommend service 
as little is known 
about it.
Training provided-based 
on materials and models 
produced in partnership 
with the Cancer Society.  
11 pharmacists from 
ethnic minorities 
are also trained to 
provide services to this 
population group.  
Quit rate is 30% at 52 weeks.
Brief consultation service 
tested in 25 pharmacies.  145 
pharmacies offer individual 
smoking cessation services, 
151 pharmacies offer group 
services.
NRT not covered in 
funded/subsidised 
schemes.
Cooperation with national state will end 
in 2007 and be replaced with municipal 
based cooperation.
Future programs will target pregnant 
smokers and those with diabetes and heart 
disease.
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Appendix II: International Smoking Cessation Services Summary (continued)
Country Tobacco cessation activity
Economic 
incentives
Other
incentives
Infrastructure 
and support
Awareness and 
promotion
Education and 
training Outcomes Policies Comments and future plans
Finland
Adult smoking:
27% male
20% female
1,351 cigarette 
consumption 
annual pp
Personalised smoking 
cessation service 
developed in 2005.
27 private pharmacies 
and 17 university 
pharmacies (chain owned 
by University) offer PAS 
model service.  PAS model: 
4-5 visits to pharmacist 
and telephone follow up 
over 4-6 months.  
University pharmacies 
require 11 visits over 6 
months.  Blood pressure 
and CO monitored.  50 
pharmacists take part.
Kuopio area: 10 year 
cooperation with two 
pharmacies, local health 
centre and university 
hospital.
Fee charged to 
patient (60-80 
Euros).  Felt 
that there are 
few economic 
incentives.
University 
pharmacy chain 
are the main 
providers with 
150 customers.
Challenge in 
determining 
the required fee 
that patients 
are willing 
to pay.  If 
patients access 
programmes 
through other 
providers 
such as GPs or 
nurses, they still 
need to pay for 
appointments 
and for NRT.
Quit and win 
competition
Association of 
Finnish pharmacies 
(AFP) coordinates 
the anti-smoking 
group (SALSA).  
SALSA provide study 
materials, tools, 
information articles 
and bulletins, local 
educational events.
Private pharmacies 
provide their own 
infrastructure and 
support for service 
provision.
Quit and win 
competition 
promotion.  
Promotion through 
SALSA – leaflets, 
posters, newspaper 
articles.
University Pharmacy 
advertises the 
programme in the 
public media, their 
own customer 
magazines and 
brochures and in the 
pharmacies.
Nationwide education 
campaign on national 
guidelines in 2003.  
Regular training days and 
courses.  700 pharmacists 
work in the professional 
Asthma programme 
and provide smoking 
cessation services.
Kuopio University 
pharmacy chain: provide 
multidisciplinary training 
to streamline messages 
conveyed by different 
health professional 
groups.  Training given to 
undergraduate students.
Not routine.  Poor uptake of 
PAS model services.  
Kuopio: pharmacists ask 
patients who are prescribed 
pulmonary medicines on 
their smoking status. 
Variation in type of service 
provided ranging from 
comprehensive to basic 
advice on NRT.
54% of pharmacies ran 
activities outside of the 
pharmacy in workplace etc.  
Activities increased 2-4 fold 
between 2002-2003.  Some 
multidisciplinary group 
cessation practices but these 
are rare.
NRT available as general 
sale since January 2006.  
Perhaps may reduce 
motivation of pharmacists 
to provide service.  
Despite fee for service it is 
not seen as profitable.  
National guidelines state 
that pharmacies are 
responsible for good NRT 
therapy though little 
is felt to have changed 
following the introduction 
of guidelines.  
Expansion of activities since mid 1990s.  
Pharmacists and pharmacy owners lack 
economic incentives and motivation 
likely to come from a desire improve own 
competence and help people. Only 1.4% 
of respondents to a 2005 survey stated 
that they had been advised to quit by a 
pharmacy staff member. 
Observe that pharmacists are more likely 
to help those who request assistance 
rather than all smoking customers. 
Multidisciplinary models appear to be 
successful – examples in Lapua and 
Hameenlinna (group and individual 
services).
University Pharmacy chain seems to be 
the most successful with 150 customers 
taking part in the programme.  Patient 
visits take 15-30 minutes but tend to 
run overtime.  Challenges in making the 
programme more time efficient.
France
Adult smoking:
38% male
30% female
2,058 cigarette 
consumption 
annual pp
There are about 500 
specialist tobacco 
use cessation centres 
in France. Smoking 
cessation services are also 
provided by community 
pharmacies.  No national 
programme.
National survey of 
young people suggests 
pharmacists are recognized 
as leaders in this area.
None known. 
However, two 
mutuels (private 
insurers)  
have recently 
agreed to pay 
pharmacists a 
fee of E21 for 
conducting 
patient health 
checks aimed 
at enhancing 
preventive care 
and national. 
Limited public  
funding support 
for access to 
NRT and allied 
therapies 
is being 
introduced
None known. Part of World 
Health Organization 
European 
Partnership Project 
to Reduce Tobacco 
Dependence.
Among 82 pharmacists 
polled (2000), 37% had 
undergone training for 
smoking cessation and 
85% claimed to provide 
services.
Le Louarn A, 2002
Pharmacist role recognised 
by Drug Regulatory 
Agency.  No government 
contract with pharmacies 
to provide services.
Germany
Adult smoking:
39% male
31% female
1,702 cigarette 
consumption 
annual pp
“Although highly 
developed in other areas, 
the medical system 
in German-speaking 
countries has yet to be 
convinced that smoking 
cessation is not only 
necessary but feasible.”
None known. 40% of 
pharmacists 
surveyed 
did not see 
tobacco 
cessation 
services as a 
normal part of 
their work
Part of World 
Health Organization 
European 
Partnership Project 
to Reduce Tobacco 
Dependence.
Federal Union of 
German Association 
of Pharmacists
German Coalition 
against Smoking, 
German Medical 
Association, and 
German Scientific 
Society for Smoking 
Cessation.
Nicotine nasal spray is available OTC in 
pharmacies.
70% of Germans are opposed to 
legislation banning smoking in public 
spaces.
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incentives
Infrastructure 
and support
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promotion
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Finland
Adult smoking:
27% male
20% female
1,351 cigarette 
consumption 
annual pp
Personalised smoking 
cessation service 
developed in 2005.
27 private pharmacies 
and 17 university 
pharmacies (chain owned 
by University) offer PAS 
model service.  PAS model: 
4-5 visits to pharmacist 
and telephone follow up 
over 4-6 months.  
University pharmacies 
require 11 visits over 6 
months.  Blood pressure 
and CO monitored.  50 
pharmacists take part.
Kuopio area: 10 year 
cooperation with two 
pharmacies, local health 
centre and university 
hospital.
Fee charged to 
patient (60-80 
Euros).  Felt 
that there are 
few economic 
incentives.
University 
pharmacy chain 
are the main 
providers with 
150 customers.
Challenge in 
determining 
the required fee 
that patients 
are willing 
to pay.  If 
patients access 
programmes 
through other 
providers 
such as GPs or 
nurses, they still 
need to pay for 
appointments 
and for NRT.
Quit and win 
competition
Association of 
Finnish pharmacies 
(AFP) coordinates 
the anti-smoking 
group (SALSA).  
SALSA provide study 
materials, tools, 
information articles 
and bulletins, local 
educational events.
Private pharmacies 
provide their own 
infrastructure and 
support for service 
provision.
Quit and win 
competition 
promotion.  
Promotion through 
SALSA – leaflets, 
posters, newspaper 
articles.
University Pharmacy 
advertises the 
programme in the 
public media, their 
own customer 
magazines and 
brochures and in the 
pharmacies.
Nationwide education 
campaign on national 
guidelines in 2003.  
Regular training days and 
courses.  700 pharmacists 
work in the professional 
Asthma programme 
and provide smoking 
cessation services.
Kuopio University 
pharmacy chain: provide 
multidisciplinary training 
to streamline messages 
conveyed by different 
health professional 
groups.  Training given to 
undergraduate students.
Not routine.  Poor uptake of 
PAS model services.  
Kuopio: pharmacists ask 
patients who are prescribed 
pulmonary medicines on 
their smoking status. 
Variation in type of service 
provided ranging from 
comprehensive to basic 
advice on NRT.
54% of pharmacies ran 
activities outside of the 
pharmacy in workplace etc.  
Activities increased 2-4 fold 
between 2002-2003.  Some 
multidisciplinary group 
cessation practices but these 
are rare.
NRT available as general 
sale since January 2006.  
Perhaps may reduce 
motivation of pharmacists 
to provide service.  
Despite fee for service it is 
not seen as profitable.  
National guidelines state 
that pharmacies are 
responsible for good NRT 
therapy though little 
is felt to have changed 
following the introduction 
of guidelines.  
Expansion of activities since mid 1990s.  
Pharmacists and pharmacy owners lack 
economic incentives and motivation 
likely to come from a desire improve own 
competence and help people. Only 1.4% 
of respondents to a 2005 survey stated 
that they had been advised to quit by a 
pharmacy staff member. 
Observe that pharmacists are more likely 
to help those who request assistance 
rather than all smoking customers. 
Multidisciplinary models appear to be 
successful – examples in Lapua and 
Hameenlinna (group and individual 
services).
University Pharmacy chain seems to be 
the most successful with 150 customers 
taking part in the programme.  Patient 
visits take 15-30 minutes but tend to 
run overtime.  Challenges in making the 
programme more time efficient.
France
Adult smoking:
38% male
30% female
2,058 cigarette 
consumption 
annual pp
There are about 500 
specialist tobacco 
use cessation centres 
in France. Smoking 
cessation services are also 
provided by community 
pharmacies.  No national 
programme.
National survey of 
young people suggests 
pharmacists are recognized 
as leaders in this area.
None known. 
However, two 
mutuels (private 
insurers)  
have recently 
agreed to pay 
pharmacists a 
fee of E21 for 
conducting 
patient health 
checks aimed 
at enhancing 
preventive care 
and national. 
Limited public  
funding support 
for access to 
NRT and allied 
therapies 
is being 
introduced
None known. Part of World 
Health Organization 
European 
Partnership Project 
to Reduce Tobacco 
Dependence.
Among 82 pharmacists 
polled (2000), 37% had 
undergone training for 
smoking cessation and 
85% claimed to provide 
services.
Le Louarn A, 2002
Pharmacist role recognised 
by Drug Regulatory 
Agency.  No government 
contract with pharmacies 
to provide services.
Germany
Adult smoking:
39% male
31% female
1,702 cigarette 
consumption 
annual pp
“Although highly 
developed in other areas, 
the medical system 
in German-speaking 
countries has yet to be 
convinced that smoking 
cessation is not only 
necessary but feasible.”
None known. 40% of 
pharmacists 
surveyed 
did not see 
tobacco 
cessation 
services as a 
normal part of 
their work
Part of World 
Health Organization 
European 
Partnership Project 
to Reduce Tobacco 
Dependence.
Federal Union of 
German Association 
of Pharmacists
German Coalition 
against Smoking, 
German Medical 
Association, and 
German Scientific 
Society for Smoking 
Cessation.
Nicotine nasal spray is available OTC in 
pharmacies.
70% of Germans are opposed to 
legislation banning smoking in public 
spaces.
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Country Tobacco cessation activity
Economic 
incentives
Other
incentives
Infrastructure 
and support
Awareness and 
promotion
Education and 
training Outcomes Policies Comments and future plans
India
Adult smoking:
29% male
2.5% female
129 cigarette 
consumption 
annual pp
No regular activities.  
No known models of 
pharmacist led tobacco 
cessation services
Indian Pharmaceutical 
Association: pharmacists 
active in campaigns for 
World No Tobacco Day 
and National Pharmacy 
Week.
Survey conducted to 
examine attitudes of 
pharmacists.
India is 2nd largest tobacco producer.  86% of tobacco sales in India are bidi 
(pipe), chewing tobacco, gutka.  Smuggled cigarette market is 4.4 billion USD.
Survey results:  
Survey conducted in 3 regions, 429 respondents (107 community, 88 other, 234 
students).
11% pharmacists in study are users of tobacco.  
80% pharmacists felt their current knowledge of smoking was sufficient.  
75% said that they advise customers to stop smoking.  However only 50% 
of pharmacists volunteer information about smoking cessation programs to 
customers that want to quit.
Almost all felt that they have a role to play towards a 
tobacco free future.  
Campaign: 
National pharmacy week committee sent a smoking 
cessation promotion kit to 10,000 members of the IPA, 
65 state and local branches and 500 degree and diploma 
pharmacy institutions.  Sessions on NRT were conducted. 
Media and awareness generated.
Government passed the 
Cigarettes and other 
Tobacco Products Act 
2001.
Variable state level 
enforcement.
Government of Karnataka 
have banned smoking in 
public places.
IPA to prepare and implement Guidelines 
for Pharmacists for a Tobacco Free Future.
Karnataka state: draft concept paper 
prepared to develop tobacco cessation 
program.  Not yet initiated due to lack 
of resources and time.  Request a manual 
from FIP to assist in training pharmacists 
to provide services.
Italy
Adult smoking:
32% male
17% female
1,901 cigarette 
consumption 
annual pp
No regular activities.
No known models of 
pharmacist led tobacco 
cessation services
Italian tobacco cessation 
programmes are primarily  
GP-mediated
An anti-smoking program for the prevention of cancer and cardiovascular 
diseases has been ongoing in Italy since 1981, coordinated by the National 
Cancer Institute of Genoa and the Italian League Against Cancer of Genoa. 
The program includes several initiatives addressed to different target groups; 
schoolchildren and teachers, military personnel, doctors and nurses, and 
women. No pharmacist activities are discussed in a review of these programs 
published in 1995.
Pizzo, et al (Tumori, 2003) report the results from a phone interview of 729 
family doctors, 409 in Northern and 320 in Southern Italy, regarding their 
personal smoking habits and their approach with patients on the topic. The 
percentage of current smokers among GPs included in the survey was 28.3%, 
with a higher prevalence in the south (33.3%). Most of 
the GPs believe that it is their duty to give information 
about smoking cessation (96.8%) and consider giving 
information about smoking cessation to their patients 
an important intervention (98.5%), but only about 49% 
think their patients will accept their advice. Most GPs 
(87.3%) declared having discussed about tobacco use with 
their patients during the month preceding the interview, 
and 83.5% would like to be trained on smoking cessation 
strategies. 
An official ban on 
smoking in all enclosed 
public places has been 
in place since January 
2005, resulting in an 8% 
reduction in cigarette 
consumption. (Gallus, 
2006)
Resistance, associated with 
restaurant/bar owners 
being fined if they don’t 
enforce the laws, has been 
high.
The Pharmaceutical Society (SISF) have 
no text related to tobacco cessation on 
their website and officials there did not 
responded to requests for information 
re: tobacco cessation activities by 
pharmacists.
Malaysia
Adult smoking:
49% male
3.5% female
910 cigarette 
consumption 
annual pp
Certified smoking 
cessation service provider 
(CSCSP) programme 
run by Malaysian 
Pharmaceutical Society 
from 2004.
Two known examples 
where pharmacists actively 
provide services – clinics 
are attached to teaching 
universities (USM, UKM).
None Certification 
to provide 
smoking 
cessation 
services.  Quit 
and win 
contest.
Organised by 
Malaysian 
pharmaceutical 
society.  Main 
funder is Pfizer.  
Trained facilitators 
run the workshops 
and trained 
pharmacists are 
monitored.
MPS promotion 
to pharmacists.  
Collaboration with 
Clearing House for 
Tobacco Control, 
Malaysian Academy 
for Pharmacy, 
Ministry of Health 
(Public health dept), 
and Pfizer.
Home study manual, 
workshop, participation 
in government run 
quit smoking clinic.  5 
workshops run in 2004, 
10 in 2005, 3 in 2006.  
Total of 540 pharmacists 
trained (32% of community 
pharmacists).
USM clinic data from 129 
male smokers over period 
of 34.5 months.  Average 
duration of consultation: 
15 minutes.  Quit rate for 
gum= 24%.  Quit rate for 
gum+patch=30%
Draft Tobacco Control 
Act.  Control of Tobacco 
Products Regulations.  
Tobacco tax increases.
Programme is being evaluated for 
effectiveness.  No financial incentive 
to provide services.  Appears that 
pharmacists do not actively provide 
services.  Possibly due to no sole 
dispensing rights for pharmacists.  
Hope to achieve dispensing rights in 
2008.  Nurses and dental association are 
becoming involved.
Norway
Adult smoking:
31% male
32% female
725 cigarette 
consumption 
annual pp
Pilot project involving 19 
community pharmacies.  
January-April 2006.  
Organised by professional 
body: Apotekforeningen
Customers given 5 free 
consultations at the 
pharmacy.
None. Publicity – 
articles about 
services in 
newspaper.
Financial report 
for project given 
by Directorate of 
Health and Social 
Affairs, Pfizer, 
Novartis, Stiftelsen 
til fremme av norsk 
apotekfarmasi.
Marketing campaign 
to inform local 
companies, health 
services, physicians.  
Advertised in 
newspapers, radio, 
newspaper website, 
leaflets.
Most effective: 
newspaper adverts 
and articles, 
recruiting activities 
in the pharmacy.
Two day training course 
for 9 pharmacists and 10 
pharmacy technicians.
118 customers enrolled.  
Most customers used NRT. 
35% (41) customers stopped 
smoking. 
48% (57) customers dropped 
out of project. 
Directorate of Health 
and Social Affairs have 
national campaigns.  No 
central role for pharmacies 
in policies yet.
Continue to train pharmacists and 
technicians.  Arrange a new course for 
January 2007.  Most of the pharmacies in 
the 2006 project do not provide regular 
smoking cessation services.
Current focus: demonstrate that 
pharmacists succeed in helping customers 
to quit smoking.  
Next step: Aim to develop ongoing 
services.  Hope to engage Directorate in 
discussions in 2007 on how smoking 
cessation services could be funded.
Portugal
Adult smoking:
30% male
7% female
2,079 cigarette 
consumption 
annual pp
National Association 
of Pharmacies (ANF) 
launched structured 
smoking cessation 
service through national 
campaign in May 2006.  
None.  
Discount on 
purchasing OTC 
medications for 
pharmacies.
ANF support.  
Support from 
pharmaceutical 
companies with 
OTC products 
– some provided 
special promotions 
to pharmacies.
Pharmaceutical 
Society also 
has campaigns 
on smoking 
cessation and role 
of pharmacist.  
National campaign 
publicity.
Training materials 
provided.
1430 (from 2700) pharmacies 
participated.  Data received 
from 180 pharmacies 
– awaiting results of analysis.
New law proposed on 
Tobacco and smoking 
prevention – states that 
pharmacies should play 
a role.
Pharmacists were to assess addiction level, 
provide counselling, develop an action 
plan with customer, provide regular follow 
up for <3 months, refer if necessary.
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Country Tobacco cessation activity
Economic 
incentives
Other
incentives
Infrastructure 
and support
Awareness and 
promotion
Education and 
training Outcomes Policies Comments and future plans
India
Adult smoking:
29% male
2.5% female
129 cigarette 
consumption 
annual pp
No regular activities.  
No known models of 
pharmacist led tobacco 
cessation services
Indian Pharmaceutical 
Association: pharmacists 
active in campaigns for 
World No Tobacco Day 
and National Pharmacy 
Week.
Survey conducted to 
examine attitudes of 
pharmacists.
India is 2nd largest tobacco producer.  86% of tobacco sales in India are bidi 
(pipe), chewing tobacco, gutka.  Smuggled cigarette market is 4.4 billion USD.
Survey results:  
Survey conducted in 3 regions, 429 respondents (107 community, 88 other, 234 
students).
11% pharmacists in study are users of tobacco.  
80% pharmacists felt their current knowledge of smoking was sufficient.  
75% said that they advise customers to stop smoking.  However only 50% 
of pharmacists volunteer information about smoking cessation programs to 
customers that want to quit.
Almost all felt that they have a role to play towards a 
tobacco free future.  
Campaign: 
National pharmacy week committee sent a smoking 
cessation promotion kit to 10,000 members of the IPA, 
65 state and local branches and 500 degree and diploma 
pharmacy institutions.  Sessions on NRT were conducted. 
Media and awareness generated.
Government passed the 
Cigarettes and other 
Tobacco Products Act 
2001.
Variable state level 
enforcement.
Government of Karnataka 
have banned smoking in 
public places.
IPA to prepare and implement Guidelines 
for Pharmacists for a Tobacco Free Future.
Karnataka state: draft concept paper 
prepared to develop tobacco cessation 
program.  Not yet initiated due to lack 
of resources and time.  Request a manual 
from FIP to assist in training pharmacists 
to provide services.
Italy
Adult smoking:
32% male
17% female
1,901 cigarette 
consumption 
annual pp
No regular activities.
No known models of 
pharmacist led tobacco 
cessation services
Italian tobacco cessation 
programmes are primarily  
GP-mediated
An anti-smoking program for the prevention of cancer and cardiovascular 
diseases has been ongoing in Italy since 1981, coordinated by the National 
Cancer Institute of Genoa and the Italian League Against Cancer of Genoa. 
The program includes several initiatives addressed to different target groups; 
schoolchildren and teachers, military personnel, doctors and nurses, and 
women. No pharmacist activities are discussed in a review of these programs 
published in 1995.
Pizzo, et al (Tumori, 2003) report the results from a phone interview of 729 
family doctors, 409 in Northern and 320 in Southern Italy, regarding their 
personal smoking habits and their approach with patients on the topic. The 
percentage of current smokers among GPs included in the survey was 28.3%, 
with a higher prevalence in the south (33.3%). Most of 
the GPs believe that it is their duty to give information 
about smoking cessation (96.8%) and consider giving 
information about smoking cessation to their patients 
an important intervention (98.5%), but only about 49% 
think their patients will accept their advice. Most GPs 
(87.3%) declared having discussed about tobacco use with 
their patients during the month preceding the interview, 
and 83.5% would like to be trained on smoking cessation 
strategies. 
An official ban on 
smoking in all enclosed 
public places has been 
in place since January 
2005, resulting in an 8% 
reduction in cigarette 
consumption. (Gallus, 
2006)
Resistance, associated with 
restaurant/bar owners 
being fined if they don’t 
enforce the laws, has been 
high.
The Pharmaceutical Society (SISF) have 
no text related to tobacco cessation on 
their website and officials there did not 
responded to requests for information 
re: tobacco cessation activities by 
pharmacists.
Malaysia
Adult smoking:
49% male
3.5% female
910 cigarette 
consumption 
annual pp
Certified smoking 
cessation service provider 
(CSCSP) programme 
run by Malaysian 
Pharmaceutical Society 
from 2004.
Two known examples 
where pharmacists actively 
provide services – clinics 
are attached to teaching 
universities (USM, UKM).
None Certification 
to provide 
smoking 
cessation 
services.  Quit 
and win 
contest.
Organised by 
Malaysian 
pharmaceutical 
society.  Main 
funder is Pfizer.  
Trained facilitators 
run the workshops 
and trained 
pharmacists are 
monitored.
MPS promotion 
to pharmacists.  
Collaboration with 
Clearing House for 
Tobacco Control, 
Malaysian Academy 
for Pharmacy, 
Ministry of Health 
(Public health dept), 
and Pfizer.
Home study manual, 
workshop, participation 
in government run 
quit smoking clinic.  5 
workshops run in 2004, 
10 in 2005, 3 in 2006.  
Total of 540 pharmacists 
trained (32% of community 
pharmacists).
USM clinic data from 129 
male smokers over period 
of 34.5 months.  Average 
duration of consultation: 
15 minutes.  Quit rate for 
gum= 24%.  Quit rate for 
gum+patch=30%
Draft Tobacco Control 
Act.  Control of Tobacco 
Products Regulations.  
Tobacco tax increases.
Programme is being evaluated for 
effectiveness.  No financial incentive 
to provide services.  Appears that 
pharmacists do not actively provide 
services.  Possibly due to no sole 
dispensing rights for pharmacists.  
Hope to achieve dispensing rights in 
2008.  Nurses and dental association are 
becoming involved.
Norway
Adult smoking:
31% male
32% female
725 cigarette 
consumption 
annual pp
Pilot project involving 19 
community pharmacies.  
January-April 2006.  
Organised by professional 
body: Apotekforeningen
Customers given 5 free 
consultations at the 
pharmacy.
None. Publicity – 
articles about 
services in 
newspaper.
Financial report 
for project given 
by Directorate of 
Health and Social 
Affairs, Pfizer, 
Novartis, Stiftelsen 
til fremme av norsk 
apotekfarmasi.
Marketing campaign 
to inform local 
companies, health 
services, physicians.  
Advertised in 
newspapers, radio, 
newspaper website, 
leaflets.
Most effective: 
newspaper adverts 
and articles, 
recruiting activities 
in the pharmacy.
Two day training course 
for 9 pharmacists and 10 
pharmacy technicians.
118 customers enrolled.  
Most customers used NRT. 
35% (41) customers stopped 
smoking. 
48% (57) customers dropped 
out of project. 
Directorate of Health 
and Social Affairs have 
national campaigns.  No 
central role for pharmacies 
in policies yet.
Continue to train pharmacists and 
technicians.  Arrange a new course for 
January 2007.  Most of the pharmacies in 
the 2006 project do not provide regular 
smoking cessation services.
Current focus: demonstrate that 
pharmacists succeed in helping customers 
to quit smoking.  
Next step: Aim to develop ongoing 
services.  Hope to engage Directorate in 
discussions in 2007 on how smoking 
cessation services could be funded.
Portugal
Adult smoking:
30% male
7% female
2,079 cigarette 
consumption 
annual pp
National Association 
of Pharmacies (ANF) 
launched structured 
smoking cessation 
service through national 
campaign in May 2006.  
None.  
Discount on 
purchasing OTC 
medications for 
pharmacies.
ANF support.  
Support from 
pharmaceutical 
companies with 
OTC products 
– some provided 
special promotions 
to pharmacies.
Pharmaceutical 
Society also 
has campaigns 
on smoking 
cessation and role 
of pharmacist.  
National campaign 
publicity.
Training materials 
provided.
1430 (from 2700) pharmacies 
participated.  Data received 
from 180 pharmacies 
– awaiting results of analysis.
New law proposed on 
Tobacco and smoking 
prevention – states that 
pharmacies should play 
a role.
Pharmacists were to assess addiction level, 
provide counselling, develop an action 
plan with customer, provide regular follow 
up for <3 months, refer if necessary.
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Appendix II: International Smoking Cessation Services Summary (continued)
Country Tobacco cessation activity
Economic 
incentives
Other
incentives
Infrastructure 
and support
Awareness and 
promotion
Education and 
training Outcomes Policies Comments and future plans
Singapore
Adult smoking:
27% male
3% female
1,230 cigarette 
consumption 
annual pp
Pharmaceutical Society 
of Singapore (PSS) 
partnered with Pfizer to 
provide patient education 
campaign ‘the goodness 
of life starts here’. 
Pharmacists in community 
and hospital provide 4 
week quit services and 
brief advice.  Government 
polyclinics which are 
government subsidized 
primary health centres 
also offer cessation services 
in their pharmacies.  
Community 
pharmacy 
services are 
free although 
charges apply at 
polyclinics for 
a consultation 
with a cessation 
consultant.  
Hospital 
pharmacy 
programmes 
also offered at 
a small charge.  
Workplace 
cessation 
services 
provided at a 
charge.
Health 
Promotion 
Board (HPB) 
certifies 
trained 
pharmacists.  
Certification 
is not 
compulsory 
but allows 
pharmacists 
to become 
trainers.  Some 
pharmacists 
are also youth 
counsellors 
for smoking 
cessation.
PSS provide 
counselling 
materials and 
certifies pharmacists 
to provide services 
– funded by Pfizer.  
HPB provides 
training and 
certification.  
Campaign: 
pharmacists 
interviewed on 
radio, TV.  Press 
conference held 
in a pharmacy.  
Pharmacists also 
run quit booths at 
community fairs 
and advertise their 
pharmacy.
Training and counselling 
materials provided by 
PSS.
Some pharmacies are 
approved to provide 
workplace education and 
counselling services.  Quit 
Centre Pharmacies have been 
set up by pharmacy chains 
which provide free services.
Hospital inpatient and 
outpatient pharmacist 
cessation services offered.
HPB runs smoking 
cessation campaign each 
year and provides support 
materials. Government 
scheme requires all 
inpatient smokers in 
participating hospitals be 
counseled on cessation.  
Government policy also 
requires all under 18 year 
old smokers to go through 
a cessation programme.
PSS smoking cessation workgroup 
publish practice and counselling 
guidelines together with HPB.  All 
trained pharmacists to provide smoking 
cessation support in a 4 week programme.  
Certified pharmacists are also able to 
train other pharmacists. Most community 
pharmacists offer brief advice services and 
some Quit Centre pharmacies provide a 4 
week programme.
Sweden
Adult smoking:
19% male
19% female
1,202 cigarette 
consumption 
annual pp
National pharmacist-
led tobacco cessation 
service provided through 
state owned pharmacies, 
Apoteket.
Telephone support 
service provided by 
trained tobacco cessation 
counsellors as well as 
individual counselling 
programme.
Individual and group 
tobacco cessation services 
provided.  Group services 
typically provided to 
workplaces (10 sessions in 
one year).
No economic 
incentives given 
to providers.  
Individual 
tobacco 
cessation 
programme 
not funded by 
government 
despite 
pharmacies 
being owned 
by the state.  
Customer 
to pay fees 
of around 
60 Euros to 
complete 
programme.
Certification 
for trained 
pharmacists 
(not 
compulsory).  
Some 
pharmacists 
also certified 
youth 
counsellors 
for smoking 
cessation.
Apoteket provide 
training, support 
and materials for 
the services across 
the national chain. 
Services advertised 
in the pharmacies.  
Group cessation 
services advertised to 
businesses.
Pharmacists are trained 
to be tobacco cessation 
counsellors, health 
coaches and in goal 
setting and  Motivational 
Interviewing.  150 
health coaches have 
been trained thus far to 
provide services.
60 trained tobacco 
cessation counsellors 
provide free telephone 
service. 
30% smoke free at the end of 
52 weeks via the individual 
and group cessation 
programmes.
Tobacco is one of the 11 
public health areas of 
focus since 2003.  Tobacco 
control interventions is 
said to comprise 0.001% 
(=11 million Euros) of the 
total costs for the Swedish 
healthcare system. Out 
of these, 1 million Euros 
were dedicated for tobacco 
prevention.
Apoteket state that limited uptake of 
services is due to limited support by 
the government in funding/subsidising 
programmes.  Experience difficulty in 
expanding services for this reason.  Future 
of tobacco services from pharmacies is 
uncertain as government monopoly of 
pharmacies is likely to be removed in the 
near future.
United States
Adult smoking:
25% male
21% female
2,255 cigarette 
consumption 
annual pp
There are numerous 
published descriptions of 
pharmacist-led tobacco 
cessation programmes 
in the US.  In general, 
these programmes report 
moderate effectiveness 
for smokers who enroll, 
but with typically low 
recruitment rates even 
when well-supported by 
trained staff and resources.
Tommasello, 1997
Kennedy, 2002
Tran, 2002
Zillich, 2002
Aquilino, 2003
Kennedy, 2004
Zillich, 2004 
Roth, 2005 
Purcell, 2006
Varying, as 
part of other 
disease state 
management 
programme 
efforts (eg, 
state Medicaid 
programmes, 
Medicare MTM 
services).
Although it 
is logical that 
reimbursement 
for tobacco 
cessation 
counselling 
would enhance 
pharmacist 
activity in this 
area, there are 
no US data to 
describe the 
breadth of 
reimbursement 
across the 
variety of 
programmes 
available.  
Quitters 
report that 
46% would 
be either 
very likely 
or extremely 
likely to 
meet with a 
pharmacist 
one-on-one 
about tobacco 
cessation if 
a nominal 
($10 USD) 
co-payment 
were required.  
This increases 
to 68% if the 
service was 
provided 
at no cost. 
(Hudmon, 
JAPhA, 2003)
The primary 
professional 
organisation 
promoting US 
pharmacist-led 
tobacco programmes 
is ASHP, where the 
National Pharmacy 
Partnership for 
Tobacco Cessation 
is housed.  NPPTC 
is a comprehensive 
effort to provide 
pharmacists with 
the resources to 
empower smokers 
to quit. It’s funded 
by the Smoking 
Cessation Leadership 
Center and the 
Robert Wood 
Johnson Foundation. 
APhA has passed 
professional 
legislation to support 
having a designated 
field in all patient 
records including 
pharmacy electronic 
dispensing systems 
for collection of 
tobacco use data.
http://www.ashp.
org/s_ashp/bin.asp?
CID=2039&DID=646
0&DOC=FILE.PDF
Rx for Change: 
Clinician-Assisted 
Tobacco Cessation is a 
comprehensive, tobacco 
cessation training 
program that equips 
health professional 
students and licensed 
clinicians with state-
of-the-art knowledge 
and skills for assisting 
patients with quitting. 
The program is based 
on principles set 
forth in the US Public 
Health Service Clinical 
Practice Guideline 
for Treating Tobacco 
Use and Dependence. 
Dissemination of the 
Rx for Change materials 
to all US schools of 
pharmacy is made 
possible by a grant from 
the National Cancer 
Institute.
Discussions with the leaders 
of successful community 
pharmacy-based programmes 
suggest that the “Ask – Advise 
– Refer” model is most 
appropriate for widespread 
use in US community 
pharmacies.  In addition, 
they found that training 
the technician to perform 
the “Ask” step will increase 
the number of patients 
successfully recruited into 
cessation programmes.
The following NRT 
products are available 
without prescription in 
the US – gum, lozenge, 
patches.  These items 
can be sold in any retail 
establishment (not only in 
pharmacies).  
Reports of pharmacists 
storing NRT products 
behind the counter are 
linked more to risk of 
pilferage than to the 
opportunity to counsel.
Despite numerous resolutions set forth by 
pharmacy organisations over the past 3 
decades, many community pharmacies in 
the US continue to sell tobacco products.
Health insurance coverage of medication 
& counselling increases use among the 
population.  Although 66% of Americans 
under the age of 65 are insured, only 
24% of programmes offer any coverage 
of tobacco cessation treatment. The 
Clinical Practice Guidelines and the 
Community Preventive Services Task Force 
recommend that all insurers pay for both 
medications and counselling for tobacco 
cessation.  Some private and state-funded 
programmes are beginning pilot projects 
to pay for tobacco cessation.
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Country Tobacco cessation activity
Economic 
incentives
Other
incentives
Infrastructure 
and support
Awareness and 
promotion
Education and 
training Outcomes Policies Comments and future plans
Singapore
Adult smoking:
27% male
3% female
1,230 cigarette 
consumption 
annual pp
Pharmaceutical Society 
of Singapore (PSS) 
partnered with Pfizer to 
provide patient education 
campaign ‘the goodness 
of life starts here’. 
Pharmacists in community 
and hospital provide 4 
week quit services and 
brief advice.  Government 
polyclinics which are 
government subsidized 
primary health centres 
also offer cessation services 
in their pharmacies.  
Community 
pharmacy 
services are 
free although 
charges apply at 
polyclinics for 
a consultation 
with a cessation 
consultant.  
Hospital 
pharmacy 
programmes 
also offered at 
a small charge.  
Workplace 
cessation 
services 
provided at a 
charge.
Health 
Promotion 
Board (HPB) 
certifies 
trained 
pharmacists.  
Certification 
is not 
compulsory 
but allows 
pharmacists 
to become 
trainers.  Some 
pharmacists 
are also youth 
counsellors 
for smoking 
cessation.
PSS provide 
counselling 
materials and 
certifies pharmacists 
to provide services 
– funded by Pfizer.  
HPB provides 
training and 
certification.  
Campaign: 
pharmacists 
interviewed on 
radio, TV.  Press 
conference held 
in a pharmacy.  
Pharmacists also 
run quit booths at 
community fairs 
and advertise their 
pharmacy.
Training and counselling 
materials provided by 
PSS.
Some pharmacies are 
approved to provide 
workplace education and 
counselling services.  Quit 
Centre Pharmacies have been 
set up by pharmacy chains 
which provide free services.
Hospital inpatient and 
outpatient pharmacist 
cessation services offered.
HPB runs smoking 
cessation campaign each 
year and provides support 
materials. Government 
scheme requires all 
inpatient smokers in 
participating hospitals be 
counseled on cessation.  
Government policy also 
requires all under 18 year 
old smokers to go through 
a cessation programme.
PSS smoking cessation workgroup 
publish practice and counselling 
guidelines together with HPB.  All 
trained pharmacists to provide smoking 
cessation support in a 4 week programme.  
Certified pharmacists are also able to 
train other pharmacists. Most community 
pharmacists offer brief advice services and 
some Quit Centre pharmacies provide a 4 
week programme.
Sweden
Adult smoking:
19% male
19% female
1,202 cigarette 
consumption 
annual pp
National pharmacist-
led tobacco cessation 
service provided through 
state owned pharmacies, 
Apoteket.
Telephone support 
service provided by 
trained tobacco cessation 
counsellors as well as 
individual counselling 
programme.
Individual and group 
tobacco cessation services 
provided.  Group services 
typically provided to 
workplaces (10 sessions in 
one year).
No economic 
incentives given 
to providers.  
Individual 
tobacco 
cessation 
programme 
not funded by 
government 
despite 
pharmacies 
being owned 
by the state.  
Customer 
to pay fees 
of around 
60 Euros to 
complete 
programme.
Certification 
for trained 
pharmacists 
(not 
compulsory).  
Some 
pharmacists 
also certified 
youth 
counsellors 
for smoking 
cessation.
Apoteket provide 
training, support 
and materials for 
the services across 
the national chain. 
Services advertised 
in the pharmacies.  
Group cessation 
services advertised to 
businesses.
Pharmacists are trained 
to be tobacco cessation 
counsellors, health 
coaches and in goal 
setting and  Motivational 
Interviewing.  150 
health coaches have 
been trained thus far to 
provide services.
60 trained tobacco 
cessation counsellors 
provide free telephone 
service. 
30% smoke free at the end of 
52 weeks via the individual 
and group cessation 
programmes.
Tobacco is one of the 11 
public health areas of 
focus since 2003.  Tobacco 
control interventions is 
said to comprise 0.001% 
(=11 million Euros) of the 
total costs for the Swedish 
healthcare system. Out 
of these, 1 million Euros 
were dedicated for tobacco 
prevention.
Apoteket state that limited uptake of 
services is due to limited support by 
the government in funding/subsidising 
programmes.  Experience difficulty in 
expanding services for this reason.  Future 
of tobacco services from pharmacies is 
uncertain as government monopoly of 
pharmacies is likely to be removed in the 
near future.
United States
Adult smoking:
25% male
21% female
2,255 cigarette 
consumption 
annual pp
There are numerous 
published descriptions of 
pharmacist-led tobacco 
cessation programmes 
in the US.  In general, 
these programmes report 
moderate effectiveness 
for smokers who enroll, 
but with typically low 
recruitment rates even 
when well-supported by 
trained staff and resources.
Tommasello, 1997
Kennedy, 2002
Tran, 2002
Zillich, 2002
Aquilino, 2003
Kennedy, 2004
Zillich, 2004 
Roth, 2005 
Purcell, 2006
Varying, as 
part of other 
disease state 
management 
programme 
efforts (eg, 
state Medicaid 
programmes, 
Medicare MTM 
services).
Although it 
is logical that 
reimbursement 
for tobacco 
cessation 
counselling 
would enhance 
pharmacist 
activity in this 
area, there are 
no US data to 
describe the 
breadth of 
reimbursement 
across the 
variety of 
programmes 
available.  
Quitters 
report that 
46% would 
be either 
very likely 
or extremely 
likely to 
meet with a 
pharmacist 
one-on-one 
about tobacco 
cessation if 
a nominal 
($10 USD) 
co-payment 
were required.  
This increases 
to 68% if the 
service was 
provided 
at no cost. 
(Hudmon, 
JAPhA, 2003)
The primary 
professional 
organisation 
promoting US 
pharmacist-led 
tobacco programmes 
is ASHP, where the 
National Pharmacy 
Partnership for 
Tobacco Cessation 
is housed.  NPPTC 
is a comprehensive 
effort to provide 
pharmacists with 
the resources to 
empower smokers 
to quit. It’s funded 
by the Smoking 
Cessation Leadership 
Center and the 
Robert Wood 
Johnson Foundation. 
APhA has passed 
professional 
legislation to support 
having a designated 
field in all patient 
records including 
pharmacy electronic 
dispensing systems 
for collection of 
tobacco use data.
http://www.ashp.
org/s_ashp/bin.asp?
CID=2039&DID=646
0&DOC=FILE.PDF
Rx for Change: 
Clinician-Assisted 
Tobacco Cessation is a 
comprehensive, tobacco 
cessation training 
program that equips 
health professional 
students and licensed 
clinicians with state-
of-the-art knowledge 
and skills for assisting 
patients with quitting. 
The program is based 
on principles set 
forth in the US Public 
Health Service Clinical 
Practice Guideline 
for Treating Tobacco 
Use and Dependence. 
Dissemination of the 
Rx for Change materials 
to all US schools of 
pharmacy is made 
possible by a grant from 
the National Cancer 
Institute.
Discussions with the leaders 
of successful community 
pharmacy-based programmes 
suggest that the “Ask – Advise 
– Refer” model is most 
appropriate for widespread 
use in US community 
pharmacies.  In addition, 
they found that training 
the technician to perform 
the “Ask” step will increase 
the number of patients 
successfully recruited into 
cessation programmes.
The following NRT 
products are available 
without prescription in 
the US – gum, lozenge, 
patches.  These items 
can be sold in any retail 
establishment (not only in 
pharmacies).  
Reports of pharmacists 
storing NRT products 
behind the counter are 
linked more to risk of 
pilferage than to the 
opportunity to counsel.
Despite numerous resolutions set forth by 
pharmacy organisations over the past 3 
decades, many community pharmacies in 
the US continue to sell tobacco products.
Health insurance coverage of medication 
& counselling increases use among the 
population.  Although 66% of Americans 
under the age of 65 are insured, only 
24% of programmes offer any coverage 
of tobacco cessation treatment. The 
Clinical Practice Guidelines and the 
Community Preventive Services Task Force 
recommend that all insurers pay for both 
medications and counselling for tobacco 
cessation.  Some private and state-funded 
programmes are beginning pilot projects 
to pay for tobacco cessation.
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